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Abstract 
Emily Elisabeth Vavalle 
An Evaluation of Mandatory Communicable Disease Reporting in North Carolina 
(Under the Direction of David J. Weber, MD, MPH) 
 
The current communicable disease surveillance system in the United States largely relies on re-
porting of communicable diseases and conditions by both physicians and laboratories.  Incom-
plete or inaccurate reporting of these diseases impairs the estimation of incidence rates from sur-
veillance systems as well as hinders the implementation and evaluation of public health control 
measures.  The extent of incomplete reporting has not been quantified for a large geographic 
area over time or for more than a few diseases.  Therefore, the completeness of communicable 
disease reporting was studied using a retrospective cohort study at 8 large healthcare systems in 
North Carolina (NC) spanning a ten-year time period.  The NC Department of Health and Human 
Services (NC DHHS) communicable disease surveillance system is based on “mandatory” report-
ing of more than 60 diseases and conditions and is a passive surveillance system.  Diagnostic 
codes from healthcare system billing records were used to ascertain the eligible cases to be re-
ported to the communicable disease surveillance system, and a unique identifier was used to 
match these eligible patients to the case-patients who were reported to the NC DHHS surveil-
lance system.  In addition, a validation study was also conducted to estimate positive predictive 
values of the diagnostic codes for communicable disease case ascertainment because these 
codes are widely used for both public health surveillance and research.  Quantification of com-
municable disease reporting completeness is critical to understanding the impact on two public 
health surveillance system goals, that is, disease incidence rate estimation and public health ini-
tiation of disease transmission control measures.  In addition, these analyses may guide the de-
velopment of local, state and national strategies for improvement of disease reporting and surveil-
lance.   
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I. Chapter 1.   Background  
A. Communicable Disease Surveillance 
Surveillance has been defined as the “ongoing systematic collection, analysis and interpreta-
tion of outcome-specific data for use in the planning, implementation and evaluation of public 
health practice” [1, 2].  In the United States, public health surveillance has historically centered on 
infectious diseases and dates back to 1878 when Congress authorized the Public Health Service 
to collect morbidity data for cholera, smallpox, plague and yellow fever [3].  Together, the Centers 
for Disease Control and Prevention (CDC) and The Council of State and Territorial Epidemiolo-
gists (CSTE) select the diseases and conditions for mandatory reporting by all states and U.S. 
territories; currently, there are more than 60 reportable diseases and conditions selected for re-
porting.  However, the exact diseases reported vary somewhat among the states.  Communicable 
disease surveillance data serves a critical role in measurement of endemic incidence of disease 
in the community, recognition of disease outbreaks, assessment of prevention and control meas-
ure effectiveness, allocation of public health resources, and further understanding the epidemiol-
ogy of new and emerging pathogens [3].   
Despite evidence that active surveillance programs such as those that utilize routine tele-
phone and mail contact with physicians have been shown to be 2.6 - 4.8 times more effective 
than passive disease reporting by physicians [4], most states, including North Carolina, require 
communicable disease reporting by law [5] but rely solely on passive or voluntary reporting.   
While passive reporting systems are simple and inexpensive, they have several disadvantages 
including that the data reported may be highly variable in quality, often incomplete, and not timely 
[6-47].   
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Currently in North Carolina, disease reports are initiated on paper communicable disease 
report forms (Figure 1) and contain demographic, clinical and risk factor data for the case-patient.  
These reports are required to be submitted to the health department within a specified period of 
time (i.e., immediately, within 24 hours, or within 7 days) depending on the disease.  In all states 
and U.S. territories, healthcare providers, laboratories or both are assigned responsibility for re-
porting each case based on standardized case definitions [48].  In a study conducted by CDC and 
CSTE investigators in 1997, North Carolina had more than 70% concordance with 52 other states 
and territories for the method of reporting (i.e., physician, laboratory or both) for 34 out of 48 re-
portable diseases [49].  According to the North Carolina General Statutes [50, 51] communicable 
disease reporting is required when a physician suspects or confirms that a patient has one of the 
designated reportable diseases[52].  Other healthcare providers (e.g., nurse practitioners, physi-
cian assistants) are not required to report by NC general statutes.  The importance of healthcare 
provider-based reporting is marked by his/her ability to make a diagnosis in the absence of or 
prior to laboratory confirmation of many diseases and to play a timely role in disease transmission 
control measures [53].  For many diseases, healthcare providers can serve as an important con-
nection between medicine and public health as they have direct contact with the patient and an 
ability to provide the health department with detailed information about the patient’s illness and 
risk factors [54]. 
 In addition, in North Carolina since 1998, persons in charge of diagnostic laboratories have 
also been required to report positive laboratory results for certain diseases [55].  This secondary 
method of disease reporting was implemented to be a complement but not as a substitute to phy-
sician-based communicable disease reporting because many diseases and conditions require 
clinical correlation in addition to positive laboratory results (e.g., Rocky Mountain Spotted Fever, 
syphilis).  Institution of a dual reporting mechanism (i.e., both physician and laboratory) for many 
communicable diseases was employed in order to improve completeness, accuracy and timeli-
ness of disease reporting, and duplicate reports are reconciled at the state level.  However, the 
presumed increased effectiveness of a dual reporting mechanism (i.e., laboratories in addition to 
physicians) has not been comprehensively quantified.
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Figure 1.  Current Communicable Disease Report Form, Listing of Diseases and Time Within Which Disease Must Be Reported 
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B. Eligible Case Ascertainment Methods 
In order to assess the completeness of a surveillance system, an alternate data source must 
be chosen to identify cases eligible to be reported to the surveillance system.  Previous studies 
have employed a variety of methods to ascertain these eligible cases including active surveillance 
as well as using various existing data sources such as medical records, discharge diagnosis 
codes, Medicaid records, death certificates, and laboratory records [8].  Each of these data 
sources has advantages and disadvantages for use, and in addition, the positive predictive value 
and sensitivity of the alternate data sources should be considered.   Unfortunately, the sensitivity 
and positive predictive value of case ascertainment with these alternate methods has not been 
well studied and has been found to be low.  For example, during a community measles epidemic, 
when active surveillance was conducted via a household cluster survey that identified eligible 
cases by direct questioning parents of their children’s measles disease history and then verified 
the children’s case eligibility by a medical record review, 23% of those reported to have measles 
were found to have chickenpox on further questioning [6]. 
A commonly used method for eligible case ascertainment is the use of standardized Interna-
tional Classification of Diseases Ninth Revision-Clinical Modification codes (ICD-9-CM), which are 
often used on death certificates, in Medicaid records as well as for hospital and outpatient dis-
charge diagnoses.  Large healthcare systems employ trained medical coders who review provid-
ers’ documentation in order to assign the appropriate ICD-9-CM diagnosis code following the pa-
tient’s discharge or outpatient visit.  The designation of ICD-9-CM codes are standardized across 
healthcare systems and are designed to capture the patient’s clinical diagnosis regardless of 
laboratory confirmation.   
However, ICD-9-CM codes have been found to have variable accuracy for both healthcare 
billing [56] as well as for disease classification [57] due to both coding and physician errors, and 
have never been comprehensively validated for their use for surveillance.  In an overall assess-
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ment of the accuracy of ICD-9-CM codes for Medicare claims data, Fisher and colleagues found 
that diseases coded as infectious and parasitic diseases had 62.6-65.4% agreement with the ab-
stracted hospital data [57]. In addition, the sensitivity of ICD-9-CM codes for five infectious dis-
eases (shigellosis, salmonellosis, giardiasis, hepatitis A and hepatitis B) was only 53% (10/19) for 
inpatient cases and 7% (15/213) of outpatient cases [58].  Decreased sensitivity of ICD-9-CM 
codes in both inpatient and outpatient settings has been attributed to laboratory results not avail-
able at the time the patient visit was coded and that more complex clinical diagnoses were given 
priority over infectious disease clinical diagnosis codes.  
In addition to low sensitivity of ICD-9-CM for communicable disease surveillance, these 
codes may have low positive predictive values for communicable disease surveillance for two 
main reasons.  First, an inpatient may have had suspected disease which warranted the assign-
ment of an ICD-9-CM code, but did not meet the specific communicable disease surveillance 
case definition.  For example, the discordance of ICD-9-CM diagnostic codes and active tubercu-
losis (TB) cases have been explained by the fact that patient was suspected to have active TB at 
discharge, but the disease was not yet confirmed, the patient had screening (i.e., tuberculin skin 
test placed) for evaluation of a latent tuberculosis infection, the patient had a history of treated 
tuberculosis or that the patient had an infection due to another species of Mycobacterium [15, 17].  
Second, it is possible that the patient was mistakenly coded as having the disease in the absence 
of or presence of a similar disease.  Thirty-three percent of outpatients and 35% of inpatients 
were found to be incorrectly coded  in small validation studies of ICD-9-CM codes for communi-
cable disease surveillance [27, 59].  Only five completeness studies to date have assessed the 
positive predictive value of ICD-9-CM codes for eligible case ascertainment [7, 15, 17, 27, 45].  A 
validation of the eligible case ascertainment method is crucial to any study on reporting com-
pleteness because methods with low positive predictive value could lead to underestimates of 
true reporting completeness and methods with low sensitivity could lead to overestimates of true 
reporting completeness. 
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In addition to their use for eligible case ascertainment for assessing disease reporting pro-
portions, ICD-9-CM codes have been proposed to be used as adjuncts to existing public health 
reporting systems [60] and are key data elements of the National Healthcare Survey, National 
Ambulatory Medical Care Survey, National Hospital Ambulatory Medical Care Survey, and the 
National Hospital Discharge Survey which are commonly used for surveillance and research pur-
poses [61].  Therefore, quantifying the positive predictive value and sensitivity of ICD-9-CM codes 
for disease surveillance has utility beyond the validation of their use as an alternate data source 
for assessing reporting completeness.   
C. Disease Reporting Completeness 
Monitoring temporal and geographic disease trends requires consistency of disease report-
ing but not necessarily completeness.  However, complete disease reporting is crucial in order to 
accurately measure and compare disease incidence rates especially as diseases begin to de-
crease in incidence (e.g., measles, invasive H. influenzae disease), to quantify the risk of rare 
diseases (e.g., malaria, vaccine-associated paralytic poliomyelitis), and to implement immediate 
disease control measures and prevent further disease transmission (e.g., meningococcal menin-
gitis, pertussis, bioterrorism agents).  Surveys of healthcare providers and laboratory personnel 
have revealed numerous motives for not reporting diseases to the health department.  Reasons 
cited for not reporting include: confusion or lack of awareness over the reporting process (e.g., 
where, when and which diseases), concerns over confidentiality and privacy of the patient par-
ticularly with sexually transmitted infections, inconvenience of reporting or lack of an established 
system for reporting, perception of the unimportance of disease reporting, lack of incentives or 
feedback about reporting, assumption that another entity would report, no definitive diagnosis or 
laboratory confirmation, and that the patient already received treatment or no treatment or pre-
ventive treatment exists for the disease [32, 47, 62, 63].   In addition, rarely, if ever, are penalties 
enforced for a failure or delay of reporting a communicable disease to the health department.   
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These barriers to disease reporting contribute to incomplete reporting of diseases of public 
health concern and thereby threaten the utility of the public health surveillance system.  For ex-
ample, amidst a community-wide outbreak, cluster household surveys showed that for measles, a 
vaccine preventable disease, reporting was as low as 29% in Los Angeles [6].  Although com-
plete reporting of rare diseases in the United States, like malaria, is critical to ensure that the dis-
ease is not becoming endemic in the United States; a recent study has shown only 70% reporting 
completeness for malaria when comparing laboratory records to surveillance data [10].  Meningo-
coccal disease, a serious disease transmitted from person-to-person through respiratory droplets 
that requires immediate public health control measures for preventive treatment of close contacts 
to the source case, has been shown to have a reporting completeness as low as 23% based on 
laboratory records and death certificates in Wisconsin [29].   
Unfortunately, interpretation of previous reporting completeness studies is not straightfor-
ward.  Disease reporting completeness evaluations in the United States have been conducted for 
only a limited set of diseases with reporting proportion ranges varying considerably; diseases 
most commonly evaluated include AIDS (reporting proportions: 31-99%) [12, 36-43], tuberculosis 
(40-99.5%) [11, 12, 15-18], and other sexually transmitted infections such as chlamydia and gon-
orrhea (0-96%) [12, 24, 32, 33].  Previous studies examining completeness of disease reporting 
have differed considerably by size of geographic region (e.g., clinics at a single university to mul-
tiple states), ranged in study time period (e.g., several months to several years), evaluated differ-
ent types of reporting systems (e.g., healthcare provider-based passive reporting versus both 
healthcare provider and laboratory-based passive reporting), and employed various eligible case 
ascertainment methods (e.g., laboratory records, billing records, active surveillance, death certifi-
cates); the key components of each previous study’s design and the reporting completeness pro-
portions are shown in Table 1.   
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Table 1.  Summary of Disease Reporting Completeness Studies 
 
Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
AIDS New York City January-June 1983 Healthcare provider 
based, passive 
Lab records, log books, 
autopsy records com-
pared to health dept case 
reports 
93.6% (235/251) [39] 
AIDS Washington DC, 
New York City, 
Boston, Chicago 
July-December 1985 Healthcare provider, 
medical and laboratory 
records, active 
Death certificate review 
compared to AIDS regis-
tries 
89% (487/548) 
95% CI: (86-91%) 
[40] 
AIDS San Francisco 
Bay Area 
1985-1986 NA Death certificate/ICD9 
codes compared to AIDS 
registry 
92% (1171/1273) [41] 
AIDS South Carolina January 1986-June 
1987 
Healthcare provider 
based, passive 
Uniform billing record (UB-
82) review compared to 
health dept case registry 
59.5% (91/153) [42] 
AIDS Oregon February 1, 1986 to 
January 31, 1987 
Healthcare provider 
based, passive 
Active surveillance with 
physicians and infection 
control practitioners, ICD9 
codes, death certificates 
compared to health dept 
records 
64% (56/85)* 
95% CI: (54-74%) 
 
[43] 
AIDS/HIV Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
80% (92/115) [12] 
AIDS Alabama, Geor-
gia, Los Angeles, 
Maryland, New 
Jersey, Washing-
ton State 
1988 NA Medical care databases 
(hospital discharge re-
cords, Medicaid claims) 
compared to AIDS Report-
ing System 
92% (4157/4500)* 
95% CI: (89-96%) 
 
[35] 
AIDS San Mateo 
County,  
California 
January 1989- 
December 1990 
Healthcare provider-
based, passive 
Discharge diagnosis 
(ICD9) codes compared to 
AIDS registry 
76% (72/95) [36] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
AIDS Philadelphia Before December 31, 
1990 
NA Penn Consortium AIDS 
database compared to 
health dept records 
90.5% (267/295) [37] 
AIDS San Mateo 
County,  
California 
January-March 1991 Healthcare provider 
based, passive 
Active surveillance of AZT 
administration logs, bron-
choscopy logs, respiratory 
therapy logs, and pathol-
ogy cancer registry com-
pared to AIDS registry 
31% (4/13) [36] 
AIDS Louisiana 1994 Healthcare provider and 
laboratory based, pas-
sive 
Medical record review, 
hospital discharge and 
Medicaid datasets com-
pared to health dept re-
cords 
99% (2865/2904)* [38] 
Massachusetts 95% (1285/1353)*  
San Francisco 93% (7834/8463)* 
Amebiasis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
17% (1/6) [12] 
Botulism Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
0% (0/1) [12] 
Campylobact-
eriosis 
Pittsburgh, Penn-
sylvania 
January 1 to Novem-
ber 26, 2000 
Healthcare provider and 
laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
68% (25/37)* 
95% CI: (49-85%) 
 
[23] 
Chlamydia Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
0% (0/4) [12] 
Chlamydia Rural North Caro-
lina County 
March-April, July-
December 1993 
Healthcare provider 
based, passive 
Hospital laboratory data 
compared to health dept 
records 
55% (87/158) [32] 
Chlamydia Rural North Caro-
lina County 
May-June 1993 Healthcare provider 
based, active 
Hospital laboratory data 
compared to health dept 
records 
79% (19/24) [32] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
E .coli O157:H7 Pittsburgh, Penn-
sylvania 
January 1 to Novem-
ber 26, 2000 
Healthcare provider and 
laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
59% (10/17)* 
95% CI: (33-86%) 
 
[23] 
Giardiasis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
10% (1/10) [12] 
Giardiasis Hawaii July 1 to December 
31, 1998 
Laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
33% (26/79)* 
95% CI: (30-37%)  
[13] 
Giardiasis Pittsburgh, Penn-
sylvania 
January 1 to Novem-
ber 26, 2000 
Healthcare provider and 
laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
59% (13/22)* 
95% CI: (39-77%) 
 
[23] 
Gonorrhea Alaska May 31, 1973-May 
31, 1974 
NA Record review of 8 physi-
cians in 3 communities 
compared to health dept 
case reports 
42% (76/183)  [34] 
Gonorrhea Vermont 1982-1983 Healthcare provider 
based, passive 
Discharge diagnosis (ICD) 
codes compared to health 
dept reports 
93% (28/30) [24] 
Gonorrhea Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
96% (21/22) [12] 
Gonorrhea 3 Emergency De-
partments in the 
District of Colum-
bia 
2 months in 1989 Healthcare provider 
based, passive 
Medical record review of 
culture confirmed cases 
compared to health dept 
records 
91.5% (204/223) [33] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Gonorrhea Rural North Caro-
lina County 
March-April, July-
December 1993 
Healthcare provider 
based, passive 
Hospital laboratory data 
compared to health dept 
records 
72% (80/111) [32] 
Gonorrhea Rural North Caro-
lina County 
May-June 1993 Healthcare provider 
based, active 
Hospital laboratory data 
compared to health dept 
records 
88% (21/24) [32] 
H. influenzae 
meningitis 
11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
32% (7/22) [11] 
H. influenzae, 
invasive disease 
Tennessee April 1989-June 1992 Healthcare provider 
based, passive 
Active laboratory-based 
surveillance system com-
pared to health dept re-
cords 
49% (94/191) [9] 
H .influenzae Kentucky 1995 NA ICD9 codes validated to 
medical record review 
compared to health dept 
records 
50% (2/4) [27] 
Viral hepatitis 11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
11% (31/282) [11] 
Hepatitis non A, 
non B 
Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
0% (0/15) [12] 
Hepatitis A Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
33% (4/12) 
 
[12] 
Perinatal Hepati-
tis B 
New York State 
(excluding NYC) 
1991 Healthcare provider and 
laboratory-provider 
based, passive  
State health department 
database from newborn 
screening program com-
pared to local health dept 
records 
83% (313/378)* [31] 
Acute Hepatitis B Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
50% (10/20) [12] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Acute Hepatitis B Seattle, Washing-
ton 
June 1994-May 1998 Healthcare provider and 
laboratory based, pas-
sive 
Longitudinal Cohort study 
data from symptomatic 
seroconverter intravenous 
drug users compared to 
health dept records 
14.3% (2/14) [30] 
Acute Hepatitis C  Seattle, Washing-
ton 
June 1994-May 1998 Healthcare provider and 
laboratory based, pas-
sive 
Longitudinal Cohort study 
data from symptomatic 
seroconverter intravenous 
drug users compared to 
health dept records 
0% (0/4) [30] 
Leprosy Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
0% (0/1) [12] 
Malaria Tucson, metropoli-
tan Phoenix, Ari-
zona, San Diego 
and Imperial 
Counties, Califor-
nia, Albuquerque, 
Las Cruces, Sante 
Fe, and Espanola, 
New Mexico and 
Houston/Harris 
County, Cameron 
County and El 
Paso, Texas 
January 1 to August 
21, 1995 
NA Active laboratory surveys 
compared to health dept 
records 
70% (43/61) 
69% (43/62)* 
[10] 
Measles Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
100% (2/2) [12] 
Measles Los Angeles 1990-1991 Healthcare provider 
based, passive 
Community wide surveys 
during an outbreak veri-
fied with medical record 
review compared to health 
dept records 
29% (10/35) [6] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Measles New York City 1991 Healthcare provider 
based, passive 
Medical record review 
compared to health dept 
records 
45% (664/1487) [46] 
Meningococcal 
meningitis 
11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
50% (3/6) [11] 
Meningococcal 
Disease 
Wisconsin January 1980-
February 1982 
Healthcare provider 
based, passive 
Lab records compared to 
death certificates and 
health dept case reports 
23% (28/120)  [29] 
N. meningitidis, 
invasive disease 
Tennessee November 1989-June 
1992 
Healthcare provider 
based, passive 
Active laboratory-based 
surveillance system com-
pared to health dept re-
cords 
58% (41/71) [9] 
Meningococcal 
Disease 
New York State 
(excl NYC) 
1991 NA Statewide hospital dis-
charge records (ICD9) 
compared to health dept 
records 
93% (100/107) [7] 
N. meningitidis Pittsburgh, Penn-
sylvania 
January 1 to Novem-
ber 26, 2000 
Healthcare provider and 
laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
58% (5/9)* 
95% CI: (30-88%) 
 
[23] 
Meningococcal 
Disease 
Maine 2001-2006 Healthcare provider, 
healthcare facilities and 
laboratory based, pas-
sive 
Statewide hospital dis-
charge records (ICD9) 
with medical record review 
validation compared to 
health dept records 
98% (42/43) [45] 
Pertussis Vermont 1982-1983 Healthcare provider 
based, passive 
Discharge diagnosis (ICD) 
codes compared to health 
dept reports 
40% (6/15) [47] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Pertussis (Hospi-
talizations) 
 
United States 1985-1988 Healthcare provider 
based, passive 
Commission on Profes-
sional and Hospital Activi-
ties-Professional Activities 
Survey (ICD9 hospitaliza-
tion codes) compared to 
CDC surveillance records 
32% (4404/13557)* 
 
[28] 
Pertussis (Mor-
tality) 
 
United States 1985-1988 Healthcare provider 
based, passive 
National Center for Health 
Statistics Vital Statistics 
System (ICD9 codes on 
death certificates) com-
pared to CDC surveillance 
records 
33% (32/98)* 
 
[28] 
Pertussis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
94% (9/14) [12] 
Pertussis Kentucky 1995 NA ICD9 codes validated to 
medical record review 
compared to health dept 
records 
100% (2/2) [27] 
Poliomyelitis, 
paralytic (vac-
cine-associated) 
United States 1980-1991 Healthcare provider 
based, passive 
Data from National Vac-
cine Injury Compensation 
Program compared to 
CDC surveillance records 
94% (92/98) 
80.7% (92/114)* 
[26] 
Rubella, congeni-
tal 
United States 1970-1985 Healthcare provider 
based, passive 
National Congenital Ru-
bella Syndrome Registry 
and Birth Defects Monitor-
ing Program compared to 
incidence estimate from 
capture-recapture tech-
nique 
28% (337/1186) [25] 
Rubella, congeni-
tal 
Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
0% (0/1) [12] 
Salmonellosis 11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
42% (11/26) [11] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Salmonellosis Vermont 1982-1983 Healthcare provider 
based, passive 
Discharge diagnosis (ICD) 
codes compared to health 
dept reports 
67% (42/63) [24] 
Salmonellosis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
100% (4/4) [12] 
Salmonellosis Hawaii July 1 to December 
31, 1998 
Laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
50% (102/205)* 
95% CI: (48-51%)  
[13] 
Salmonellosis Pittsburgh, Penn-
sylvania 
January 1 to Novem-
ber 26, 2000 
Healthcare provider and 
laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
91% (32/35)* 
95% CI: (83-97%) 
 
[23] 
Shigellosis 11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
62% (21/34) [11] 
Shigellosis Wisconsin, Illinois, 
Pennsylvania, 
Michigan, New 
York, Georgia, 
Connecticut, Iowa, 
Tennessee, New 
Jersey 
1975 NA Infected, symptomatic 
patients that consulted a 
physician compared to 
patients reported to local 
health department 
21% [22] 
Shigellosis Oklahoma January 1-June 30, 
1985 
Physician and labora-
tory-based, passive 
Laboratory survey com-
pared to health dept case 
reports 
86% (69/80) [21] 
Shigellosis District of Colum-
bia 
January 1, 1978-July 
30, 1978 
Healthcare provider and 
laboratory based, pas-
sive 
Medical record review 
compared to health dept 
records 
32% (43/136) [20] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Shigellosis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
64% (10/15) [12] 
Shigellosis Hawaii July 1 to December 
31, 1998 
Laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
54% (16/30)* 
95% CI: (51-54%)  
[13] 
S. pneumoniae Hawaii July 1 to December 
31, 1998 
Laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
9% (5/55)* 
95% CI (9-9%) 
[13] 
Syphilis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
79% (23/29) [12] 
Tetanus Mortality United States 1979-1984 Healthcare provider 
based, passive 
National Center for Health 
Statistics Vital Statistics 
System (ICD9 codes on 
death certificates) com-
pared to CDC surveillance 
records 
40% (129/326)* [19] 
Tuberculosis 11 acute care 
hospitals in Wash-
ington DC 
January 1-June 31, 
1971 
Healthcare provider 
based, passive 
Discharge records com-
pared to health dept re-
cords 
63% (127/200) [11] 
Tuberculosis, 
(positive AFB 
smears or cul-
tures) 
Nassau County, 
NY 
1972 Laboratory based, pas-
sive 
Laboratory survey com-
pared to health dept re-
cords 
65% (32/49) [18] 
Tuberculosis Outpatient clinics 
at the University of 
Arizona 
June 1986-June 1988 Healthcare provider 
based, passive 
Diagnosis codes (ICD9) 
compared to health dept 
records 
40% (6/15) [12] 
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Disease Location Time Period Type of Surveillance Case ascertainment 
Method 
Results: 
Percentage (Propor-
tion) and 95% Con-
fidence Interval 
 
Reference 
Tuberculosis Massachusetts 
 
January 1, 1992- 
June 30, 1996 
Healthcare provider and 
laboratory based, pas-
sive 
ICD9 code-medical re-
cords and pharmacy re-
cord review compared to 
health dept records 
81% (35/43) [17] 
Tuberculosis Massachusetts, 
New York (excl. 
NYC), Utah, 
Washington, San 
Diego Co, CA; 3 
county areas in 
Florida and New 
Jersey 
1993-1994 NA Laboratory records, death 
certificates, discharge 
records, Medicaid data-
bases, pharmacy data-
bases compared to health 
dept records 
99.5% (2697/2711) [16] 
Tuberculosis Wisconsin 1995 Healthcare provider 
based, passive 
ICD9 codes with medical 
record review to verify 
compared to TB registry 
98% (50/51)  [15] 
Tuberculosis Wisconsin 1995 Healthcare provider 
based, passive 
Laboratory survey with 
medical record review to 
verify compared to TB 
registry 
98.9% (87/88) 
 
[15] 
Vancomycin-
resistant Entero-
cocci from a ster-
ile body site 
Connecticut 1994-1996 Laboratory based, pas-
sive 
Laboratory and infection 
control survey compared 
to health dept records 
59% (158/266) [14] 
Vancomycin-
resistant Entero-
cocci 
Hawaii July 1 to December 
31, 1998 
Laboratory based, pas-
sive 
Automated, electronic 
laboratory reporting veri-
fied by excluding false 
positive reports and dupli-
cate reports compared to 
health dept records 
22% (7/32)* 
95% CI: (19-26%)  
[13] 
* Estimated by capture-recapture methods [64] 
NA: information not available 
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Only two evaluations, to date, have examined reporting proportions for more than five dis-
eases.  In Washington D.C., in 1971, discharge diagnostic codes were used from 11 large hospi-
tals and determined the following reporting completeness proportions (i.e., number of cases re-
ported to the health department/total number of cases that occurred in the hospital): viral hepatitis 
(31/282) 11%, H.influenzae meningitis (7/22) 32%, salmonellosis (11/26) 42%, meningococcal 
meningitis (3/6) 50%, shigellosis (21/34) 62%, and tuberculosis (127/200) 63% [11].  The largest 
outpatient based study was conducted from 1986-1988 with diagnostic codes from University in 
Arizona outpatient clinics; completeness proportions for reportable diseases were found to be: 
hepatitis B (10/20) 50%, measles (2/2) 100%, pertussis (9/14) (64%), hepatitis A (4/12) 33%, 
salmonellosis (4/4) 100%, shigellosis (10/15) 64% [12].   
Because reporting proportions for communicable diseases have not been comprehensively 
described for all communicable diseases and vary considerably between studies (e.g, measles 
29% [6] vs. 100% [12]; salmonellosis 42% [11] vs. 100% [12], a comprehensive study of multiple 
reportable diseases using a standard methodology is needed to describe and compare disease 
reporting completeness proportions. 
D. Future of Communicable Disease Surveillance 
Communicable disease surveillance in North Carolina has recently been enhanced with the 
creation of the hospital-based Public Health Epidemiologist (PHE) Network.  The PHE Network is 
funded by the CDC Cooperative Agreement for Public Health Preparedness and Response, Fo-
cus Area B, Epidemiology and Surveillance Capacity and began in May 2003. The network in-
cludes 11 public health epidemiologists who are healthcare system employees funded by the 
CDC Cooperative agreement, and 1 Public Health Epidemiologist program director who is a state 
employee funded by the CDC Cooperative agreement.  Healthcare systems or networks were 
chosen to participate in the PHE network based on geopolitical considerations, region, emer-
gency department volume and bed size, and include teaching and non-teaching and public and 
private hospitals (Table 3).  The PHE Network healthcare systems are located in large cities in 
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North Carolina (i.e., Greenville, Chapel Hill, Winston-Salem, Wilmington, Greensboro, Charlotte, 
Durham, Asheville, Raleigh, and Fayetteville) and the locations by county are shown in Figure 3.  
The mission of the hospital-based public health epidemiologist program is to (1) enhance com-
munication between clinicians, hospitals, and the public health system; (2) assist with develop-
ment of a surveillance method for monitoring and detecting community-acquired infections as well 
as detection and response to potential bioterror events, and (3) provide education and heighten 
awareness for diseases of public health importance.   
 
Table 2.  List of Healthcare Systems and Statistics  
Healthcare System Hospital Type 
 
Number of 
Staffed Inpa-
tient Beds 
Inpatient Ad-
missions per 
Year 
Outpatient 
Visits per Year 
Pitt County Memorial Hospitals 
Greenville, NC 
Non-government, 
not for profit 755 34432 271246 
UNC Health Care  
Chapel Hill, NC State 690 31322 1155526 
Wake Forest University Baptist 
Medical Center  
Winston-Salem, NC 
Non-government, 
not for profit 978 34800 202021 
New Hanover Health Network 
Wilmington, NC County 658 32736 118262 
Moses Cone Health System 
Greensboro, NC 
Non-government, 
not for profit 1324 46482 572806 
Carolinas Medical Center 
Charlotte, NC 
Hospital District 
or Authority 1315 64598 1152935 
Duke University Medical Center 
Durham, NC 
Non-government, 
not for profit 761 38185 783154 
Mission Hospitals 
Asheville, NC 
Non-government, 
not for profit 721 35299 392600 
WakeMed Health and Hospitals 
Raleigh, NC 
Non-government, 
not for profit 752 41670 966534 
Cape Fear Valley Health Sys-
tem 
Fayetteville, NC 
Non-government, 
not for profit 581 29097 465713 
Durham VA Medical Center 
Durham, NC Veteran’s Affairs 232 Not Available Not Available 
Total  8768 388621 6080797 
Reference: [65] 
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Cleveland
Buncombe
Anson
Ashe
Beaufort
Bertie
Bladen
Brunswick
Burke
Caldwell
Carteret
Caswell
Catawba
Chatham
Cherokee
Clay
Columbus
Dare
Davie
Duplin
Forsyth Franklin
Gaston
Gates
Graham
Greene
Guilford
Halifax
Harnett
Hertford
Hoke
Hyde
Iredell
Jackson
Johnston
Jones
Lee
Lenoir
McDowell
Macon
Madison
Martin
Moore
Nash
Northampton
Onslow
Orange
Pamlico
Pender
Person
Pitt
Polk
Randolph
Robeson
Rockingham
Rowan
Rutherford
Sampson
Scotland
Stanly
Stokes
Surry
Swain
Transylvania
Tyrrell
Union
Wake
Warren
Washington
Watauga
Wayne
Wilkes
Wilson
Yadkin
Yancey
Chowan
Pasquotank
Perquimans
Camden
Currituck
Montgomery
Henderson
Granville
Vance
Durham
Mecklenburg
Lincoln
Cabarrus
Richmond
Cumberland
Alexander
Craven
Haywood
Alleghany
Mitchell
Avery
Alamance
Davidson
Edgecombe
New 
Hanover
Figure 2. Location of Public Health Epidemiologist Network Hospitals 
 
 
 
 
 
The most recent surveillance innovations are electronic disease reporting and automated 
disease reporting [66, 67].  Electronic disease reporting and automated disease reporting are 
terms that are often used interchangeably.  Automated disease reporting refers to an active sur-
veillance system that extracts data from medical or laboratory records for reporting and then elec-
tronically transmits the data to the health department.  Automated reporting does not require phy-
sicians’ or laboratories’ efforts for reporting cases of communicable diseases.  In Hawaii, when 
automated disease reporting was instituted in three statewide private laboratories by extracting 
data results from the laboratory databases and electronically delivering them to the health de-
partment, disease reporting increased 2.3-fold (95% CI 2.0-2.6) and the automated electronic 
reports were received 3.8 days (95% CI 2.6-5.0) earlier than standard laboratory reporting meth-
ods [13].  In Kansas City during a several month long study of automated data reporting from 
laboratory databases both improved completeness and timeliness of disease reporting were also 
observed [68].   
However, the implementation of these automated reporting systems that employ data extrac-
tion methods from laboratory databases for reporting present technical challenges because they 
rely on standard nomenclature for laboratory results, cannot be easily correlated with clinical di-
agnoses, and are often difficult to link to databases with patient demographic data needed for 
public health investigations [69, 70].  In fact, an automated electronic laboratory based reporting 
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system in Pittsburgh was found to result in no significant difference in completeness of reporting 
and a median of only 1 day of improved timeliness compared to the paper-based reporting sys-
tem; the efficiency of the automated reporting system was reportedly hampered by non-
standardized laboratory results (e.g., free text, negation), an inability to retract preliminary reports 
that were subsequently not confirmed, and low completion rates of patient demographic data 
fields [23]. 
Electronic disease reporting is a more general term and without further specification only im-
plies that reporting forms for physicians, laboratories and health departments will be electronic 
(e.g., web-based) so that communicable disease data forms once completed by a healthcare pro-
vider will be transmitted more quickly to the health departments.  In 2009, NC began to transition 
from paper-based to electronic disease reporting.  The electronic based disease reporting in NC 
will occur in several phases--the first phase which was implemented in 2009 involves electronic 
reporting from the local to the state health department; later phases will incorporate web-based 
electronic reporting forms for physicians to complete, and only limited automated retrieval of labo-
ratory results is currently planned.  The national advent of electronic disease reporting with limited 
automated reporting is unlikely to drastically improve reporting completeness because even with 
electronic based reporting mechanisms in place, the communicable disease surveillance system 
will still remain passive in that reporting will only be accomplished by the medical providers navi-
gating to a secure internet site and entering patient information.  Although the ease of reporting is 
likely to be greatly improved and the transmission time of the data is likely to be reduced with the 
implementation of electronic reporting technology, the system will continue to rely on medical 
providers to devote time and effort to complete the reporting.  
E. Conclusion 
With the advent of electronic communicable disease reporting underway in NC, it is crucial to de-
scribe and understand the impact of communicable disease reporting completeness on this sur-
veillance system.
II. Chapter 2.  Specific Aims 
Communicable disease surveillance has been used in the United States since 1878 and is the 
key method by which states measure endemic incidence of disease in the community, recognize out-
breaks of disease, assess the effectiveness of prevention and control measures, allocate public 
health resources, and further understand the epidemiology of new and/or emerging pathogens.  Cur-
rently, all states are required to report data on more than 60 notifiable or reportable diseases and 
conditions to the Centers for Disease Control and Prevention’s (CDC) National Notifiable Disease 
Surveillance System (NNDSS).  In North Carolina, communicable disease surveillance is required by 
law and is based on passive reporting by medical providers and laboratories.  Most states, including 
North Carolina, rely solely on passive reporting for NNDSS.  Passive reporting has several disadvan-
tages including that the data reported are highly variable in quality, often incomplete, and not timely.  
Despite the widespread usage of the NNDSS for public health activities, the completeness of this 
passive communicable disease reporting system has only been assessed for less than half of the 
diseases that are reportable by law [6-45], and rarely has a single study included more than 5 dis-
eases [11, 12] or spanned a wide geographic area over time.  Further, validation of the case ascer-
tainment method utilized in these studies has rarely been conducted using positive predictive values 
[7, 15, 17, 27, 45]. 
Therefore we have: 
 
• Conducted a retrospective cohort study of all inpatients and outpatients who were cared for at 
the 8 largest healthcare systems in NC during a 10 year time period and who were assigned 
a diagnostic code corresponding to a reportable communicable disease. 
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• Reviewed at least 20% of eligible case-patients’ medical records from each healthcare sys-
tem for a one year time period to quantify the positive predictive value of using diagnostic 
codes for communicable disease case ascertainment.  
 
• Matched eligible patient records from the cohort to the NC DHHS surveillance database of 
reported communicable disease cases. 
 
• Used semi-Bayesian hierarchical analysis to provide precise estimates of disease reporting 
completeness and positive predictive values of ICD-9-CM codes for communicable disease 
surveillance.   
 
Using these methods, we have addressed the following aims: 
 
Aim 1:  Determine the positive predictive value (PPV) of diagnostic codes for communicable disease 
case ascertainment and surveillance.  That is, given that a patient is assigned a diagnostic code for a 
communicable disease, the probability that the patient meets the communicable disease case defini-
tion will be determined. 
 
Rationale:  Diagnostic codes are commonly used for public health surveillance and research; how-
ever the positive predictive value of these codes for communicable disease surveillance has never 
been well described or quantified.  Results from this validation study analysis will improve the inter-
pretation of this study’s and other studies’ results and may aid in the development of electronic, 
automated surveillance systems that use diagnostic codes. 
 
Aim 2:  Describe the disease-specific completeness of state-required communicable disease report-
ing, overall state-required communicable disease reporting over a 10 year time period, and overall 
state-required communicable disease reporting for different healthcare systems. 
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Rationale:  Descriptive epidemiology on the completeness of disease reporting has never been as-
sessed comprehensively for all reportable communicable diseases.  Results of these analyses may 
be used to quantify the completeness of communicable disease case reporting by healthcare provid-
ers and to describe the public health impact of incomplete disease reporting. 
 
Aim 3:  Utilize hierarchical semi-Bayesian logistic regression analysis techniques to provide more 
precise estimates of disease-specific reporting completeness and positive predictive values of ICD-9-
CM codes.    
 
Rationale:  Bayesian analysis has rarely been employed in the field of infectious disease epidemiol-
ogy.  This type of analysis uses hierarchical techniques with variables believed to determine the 
magnitude of, or explain some variability between, the individual estimates and can be expected to 
reduce the overall mean squared error when an ensemble of measures are estimated [71]. 
 III. Chapter 3.  Methods 
A. Overall Study Design  
A retrospective cohort study was conducted at 8 NC Hospital-Based Public Health Epidemiolo-
gist (PHE) network healthcare systems.  Both inpatients and outpatients who were assigned dis-
charge diagnostic codes (ICD-9-CM) that correspond with NC reportable communicable diseases 
during the ten year study time period were included in this retrospective cohort.  ICD-9-CM diagnosis 
codes were chosen as the case ascertainment method for this cohort study based on the standardi-
zation of these codes across healthcare systems and for their independence from laboratory confir-
mation since not all CDC/NC surveillance case definitions require laboratory confirmation of a dis-
ease. 
The study included two time intervals (Figure 3): 1 January 1995 - 31 December 1997, which 
represents a time period prior to when laboratories were required by NC law to report positive labora-
tory results for communicable diseases and when only physicians were required to report by law; 1 
January 2000 to 31 December 2006, which represents a time period when both physicians and labo-
ratories were required to report communicable diseases by law, and includes the time periods both 
before and after the Hospital-based Public Health Epidemiologist (PHE) network was established.  
The years 1998-1999 are excluded from this study’s analysis because the surveillance system in NC 
was undergoing an important change during this time period as a NC law was passed in August 1998 
that required laboratories in addition to physicians to report certain communicable diseases.  The 
PHE network was established in May of 2003, and although the PHEs are not legally required to re-
port communicable diseases, one of their principal roles is to promote communicable disease report-
ing through education and liaison efforts within the hospitals.   
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Figure 3. Study Time Intervals 
Jan 1, 1995 Jan 1, 2007
1/1/96 1/1/97 1/1/98 1/1/99 1/1/00 1/1/01 1/1/02 1/1/03 1/1/04 1/1/05 1/1/06
1/1/95 - 12/31/97
Only Physicians Reporting
1/1/00 - 12/31/02
Physicians and Laboratories Reporting
8/1/98
Laboratories Required To Report
5/1/2003
PHE Network Established
1/1/05 - 12/31/06
Physicians, Labs and PHEs Reporting
 
B. Reportable Communicable Diseases 
The reportable communicable diseases included in this study are listed in Table 6; these dis-
eases include both nationally reportable diseases and some North Carolina specific diseases (e.g., 
pneumococcal meningitis).  International Classification of Diseases Ninth Revision-Clinical Modifica-
tion codes (ICD-9-CM) diagnostic codes were selected that are clinically consistent with the CDC 
communicable disease case definitions [48].  These diagnostic codes were used to query the health-
care system billing records at the 6 participating healthcare systems.  Chronic infectious diseases 
(e.g., HIV, Hepatitis B carrier) were excluded from this study because these diseases were likely to 
result in a recurring assignment of diagnostic codes when only the initial onset of disease is of inter-
est for incident disease reporting.  Diseases for which there is no specific diagnostic code (e.g., mon-
keypox, viral hemorrhagic fever) were also excluded.  In addition, some sexually transmitted infec-
tions (e.g., syphilis, chlamydia, gonorrhea) were excluded from the study because NC DHHS did not 
record patient identifiers for these diseases in their databases during the entire time periods of the 
study. 
Table 3.  List of Communicable Diseases Included in Study
Anthrax 
Botulism 
Brucellosis 
Campylobacter Infection 
Cholera 
Cryptosporidiosis 
Cyclosporiasis 
Dengue 
Diphtheria (Nasopharyngeal only) 
E.coli, Shiga Toxin-Producing Infection (including E. 
coli O157:H7) 
Ehrlichiosis, Granulocytic 
Ehrlichiosis, Monocytic (E. chaffeensis) 
Encephalitis, Arboviral (CAL, EEE, WNV, Other) 
Foodborne Disease: C. perfringens 
Foodborne Disease: Staphylococcal 
Hantavirus Infection 
Hemolytic Uremic Syndrome 
Hemophilus influenzae, Invasive Disease 
Hepatitis A 
Legionellosis 
Leptospirosis 
Listeriosis 
Lyme Disease 
Malaria 
Measles 
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Meningitis, Pneumococcal 
Meningococcal Disease 
Monkeypox 
Mumps 
Plague 
Polio, Paralytic 
Psittacosis 
Q Fever 
Rabies, Human 
Rocky Mountain Spotted Fever 
Rubella 
Rubella Congenital Syndrome 
Salmonellosis 
SARS (Coronavirus infection) 
Shigellosis 
Smallpox 
Streptococcal Infection, Group A, Invasive Disease 
Tetanus 
Toxic Shock Syndrome 
Toxic Shock Syndrome, Streptococcal 
Transmissible Spongiform Encephalopathies 
(CJD/vCJD) 
Trichinoisis 
Tuberculosis 
Tularemia 
Typhoid, Acute 
Typhus, Epidemic (louse-borne) 
Vaccinia 
Vibrio Infection, Other 
Vibrio vulnificus 
Whooping Cough (Pertussis) 
Yellow Fever
 
C. Healthcare System Databases 
The PHE Network hospitals are the 11 largest hospitals or healthcare systems in North Carolina 
(Table 1).  They include 30.6% of all beds in 147 NC hospitals (8,768/28,672 beds), 40.1% inpatient 
admissions per year at 107 NC hospitals (388,621/968,458 admissions per year), and 32.5% outpa-
tient visits per year at 106 NC hospitals (6,080,797/18,690,065 visits per year) [72].  The benefits of 
using the healthcare systems in the PHE network are that these healthcare systems are spread geo-
graphically throughout the state, account for approximately 30-40% of all inpatient and outpatient vis-
its to healthcare systems in the state, and that the PHE study co-investigators are healthcare system 
employees who already have access to case-patient records.  The use of the PHE network’s trained 
epidemiologists for gathering and reviewing patient records within each healthcare system promotes 
the internal validity of this cohort study.  Eight healthcare systems participated in the overall retro-
spective cohort study examining the completeness of disease reporting and 6 participated in the chart 
review validation of ICD-9-CM codes.   
Every healthcare system in the PHE network uses electronic records for patient billing.  These 
records include patient demographic data (e.g., name, social security number, address and county of 
guarantor) and clinical data (e.g., diagnostic codes, procedure codes, admission and discharge 
dates).  Key variables and descriptions are listed in Table 4.  In order to query each healthcare sys-
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tem patient billing records, a spreadsheet listing of reportable communicable diseases and their cor-
responding ICD-9-CM codes was prepared and reviewed with each study co-investigator at the par-
ticipating healthcare systems (Appendix 1).  A standardized data request for the medical records de-
partment at each healthcare system was prepared by the principal investigator and study co-
investigator and contained study inclusion criteria, data elements requested and preferred file formats 
(Appendix 2). 
Table 4.  Key Variables in Healthcare System Diagnosis Coding Databases  
Variable Name Description 
ADDATE Admission date or clinic visit date 
CO Patient’s county of residence 
DCDATE Discharge date or clinic visit date 
DCSTATUS Patient’s discharge status (e.g., Home Routine, Treated Released) 
DIAGNOSIS ICD9-CM code for disease “XXX.XX” 
DOB Patient’s date of birth 
DXDESC Text description of ICD9-CM code 
DXSEQ Sequence of diagnostic code 
FNAME Patient’s first name 
HOSP Hospital’s name 
ICU_CARE 
Patient with ICU care? 
Y=Yes 
N=No 
INS Insurance type (e.g., Medicare, Medicaid, Commercial, etc) 
LNAME Patient’s last name 
MRN Patient’s medical record number 
PTTYPE Type of patient (i.e., Inpatient, Outpatient, Emergency) 
RACE 
Patient’s race 
W=White 
B=Black 
H=Hispanic 
O=Other 
U=Unknown 
SEX 
Patient’s sex 
M=Male 
F=Female 
SSN Patient’s social security number 
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Variable Name Description 
SVDATE Date of clinic visit 
YEAR Year of discharge date for diagnosis 
 
D. NC DHHS Communicable Disease Surveillance Database 
During the study time period, NC’s communicable disease surveillance data was collected on 
paper forms that gathered data on demographic, clinical and disease risk factors.  Data were re-
viewed by the local health department and then mailed to NC DHHS where data were entered into an 
electronic database.  The electronic database contains confirmed, suspect and probable cases ac-
cording to standard CDC case definitions [48].  Key variables and their descriptions are listed in Table 
5.   
NC DHHS study co-investigators provided the health department database of reported commu-
nicable diseases required for determining which patients in the study cohort were reported.  The da-
tabase was queried by year of event (e.g., date of onset) for the designated study time intervals.  By 
querying based on the year of event rather than the year of report, the systematic bias introduced by 
a right truncation of case-patients diagnosed at the end of the study time period (e.g., a patient diag-
nosed on December 31, 2006 and reported on February 15, 2007) were minimized.   All available 
data elements for all included case-patients were transferred from the electronic databases to an 
electronic file.   
Table 5.  Key Variables in NC DHHS Surveillance Database 
Variable Name Description 
BIRTHDATE Case’s date of birth 
CARESITE 
Type of Hospital 
  PR=private 
  PU=public 
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Variable Name Description 
   M=military 
CD  Unique numeric code for each communicable disease   
COUNTY  Case’s county of residence 
COUNTDATE  Date entered into state TB database  
DIED 
 Whether case died? 
   0=No 
   1=Yes 
ETHNIC 
 Case’s Ethnicity 
   H=Hispanic 
   N=Non-Hispanic 
EVENTDATE  Date of Communicable Disease  (Event type provides further description of this date) 
EVENTNAME  Name of Communicable Disease 
EVENTTYPE 
 Type of Communicable Disease Date  
    (in order of preference) 
    1=Date of Onset 
    2=Date of Diagnosis 
    3=Date of Laboratory Diagnosis 
    4=Date of Report to County 
    5=Date of Report to State 
    6=Any Date Associated With Case 
FIRST  Case’s first name 
HOSPITAL 
 Was case hospitalized? 
   N=No 
   Y=Yes  
LASTNAME  Case’s last name 
MD1STNAME  Reporting physician first name  
MDINSTITUT  Reporting physician’s institution 
MDLASTNAME  Reporting physician last name 
RACE 
 Case’s Race 
   B=Black 
   W=White 
   A=Asian 
   O=Other 
REPORTDATE 
(TB cases only) 
 Date physician or lab reported case or date that the case 
walked in to local health department  
REPORTED  Date case was reported to Local Health Department 
REPYEAR  Year of report 
SEX 
 Case’s sex 
    M=Male 
    F=Female 
SSN  Case’s SSN 
SUBMITDATE 
(TB cases only) 
 Date local health department submitted case to Tuberculo-
sis Consultant 
YEAR  Year of report 
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E. Matching the Healthcare System Database to the Surveillance Database 
In order to determine the number of eligible patients that were reported to the NC DHHS’s com-
municable disease surveillance system, persons in the two databases were matched using a unique 
identifier.  Because social security number is the only unique identifier common to the two databases, 
this variable was used as the primary variable for matching along with a 2-3 digit disease code used 
administratively by the health department that corresponds to the patient’s diagnosis.  However, be-
cause ~25% of the social security number data was missing in the NC DHHS surveillance database 
and some healthcare systems did not have social security number data available for this study, a 
secondary identification variable was created using a combination of the first two letters of the last 
name, first letter of first name, date of birth and the 2-3 digit administrative communicable disease 
code.   Similar matching algorithms have been utilized in previous studies that required matching two 
registries.  In a study that involved matching TB registries, a matching algorithm that utilized the first 
two letters of the last name plus the first two letters of the last name plus the month and year of birth 
and sex, demonstrated a 99% sensitivity and has been shown to be superior to other matching meth-
ods including phonetic reduction of names (e.g., Soundex) [73].  Although this created identification 
variable may not be a truly unique identifier and may be inaccurate if patient’s names differ between 
the two systems, a secondary identification variable was necessary to account for the large number of 
records with missing social security numbers.  Social security number was used first for matching and 
if social security numbers were not available or no match was achieved with social security number 
then the created identification variable was used for matching.   
The matching process described above matches each healthcare system’s records to the NC 
DHHS surveillance records, so it is possible that a case classified as reported by one facility was ac-
tually reported by another facility.  The reporting agency name data element (i.e., MDINSTITUT) in 
the surveillance database is missing in at least ~15% of the case-patient records and is inconsistently 
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reported with no standardization of the free text entries, so it was not feasible to include this data 
element as another matching element.   
For eligible patients in the hospital database who had more than one visit in a 30-day time period 
for the same disease, all data elements from the earliest visit were retained and a new variable was 
created that enumerated the visits for that disease episode.  For tuberculosis, this time period was 
365 days.  For diseases which can only be acquired once – e.g., acute hepatitis A and paralytic polio, 
only the first instance of the disease was retained.   In addition, matching case-patients who had re-
port dates prior to their date of diagnosis at the hospital were excluded as they represented cases 
already reported to the health department.  
Unmatched cases between the two systems should be the result of either (1) the case was not 
reported, (2) the disease was clinically suspected but did not meet any of the CDC case definitions 
and therefore the case was not in the state surveillance database or (3) the incorrect assignment of 
an ICD-9-CM diagnostic code.  The possibility of non-matches between the databases due to clini-
cally suspected diseases that did not meet CDC case classification criteria or an incorrect assignment 
of ICD-9-CM codes were investigated further in the validation study described below. 
F. Validation Study Design 
Because ICD-9-CM codes were used to query the healthcare system databases to select pa-
tients eligible for reporting to the health department, an important source of error is the incorrect as-
signment of an ICD-9-CM code designated for a communicable disease (i.e., false positives).  By as-
signing ICD-9-CM codes for communicable diseases when the patient has no evidence of a current 
infection, the actual completeness of reporting will be underestimated.  The measurement error asso-
ciated with these false positive cases, that is the positive predictive value, was quantified by this vali-
dation study. 
A random sample from a single year (i.e., 2003) of patient records with diagnostic codes for 
communicable diseases was selected for review at each participating healthcare system.  Five patient 
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records, but at least 20% of case-patient records stratified by disease and by reporting status (i.e., 
reported case, not reported case) was chosen using random sampling procedures (i.e., PROC SUR-
VEYSELECT) within SAS [74].  These patient records were reviewed according the CDC’s published 
surveillance case definitions and determined to be a confirmed case, a suspect case, a probable case 
or not a case [48].  Those patients who were classified as “not a case” were investigated further to 
determine the cause for misclassification (e.g., misinterpretation of an abbreviated diagnosis or simi-
lar diagnosis, history of disease but not an acute case, clinically compatible case but not consistent 
with CDC’s case definition criteria, no evidence to substantiate diagnostic code) in order to produce a 
qualitative summarization of these reasons for misclassification. 
G. Measurements and Analysis 
1. Completeness Study Measurements 
The derivation of this cohort study population is shown in Figure 4.  The ideal study population 
for evaluating the completeness of communicable disease reporting in NC is all individuals with re-
portable communicable diseases (Population 1); however, only a subset of individuals with reportable 
communicable diseases are symptomatic (Population 2) and of those, only a subset seek health care 
for reportable communicable diseases (Population 3).  Because it is not feasible to include all North 
Carolina healthcare facilities in this evaluation, our study population was restricted to those patients 
who seek healthcare at a PHE network healthcare system (Population 4) and who are then assigned 
an ICD-9-CM diagnostic code for a reportable communicable disease (Population 5).  Population 5 is 
our study cohort and represents the denominator of the reporting completeness proportions.  If all of 
the patients who are reported to the NC DHHS communicable disease surveillance system are de-
fined as Population 6, then the patients who are in the intersection of Populations 5 and 6 represent 
the reported cases and the numerator of the reporting completeness proportion; which will be desig-
nated a.  Patients who are in Population 5, but not in Population 6 represented the unreported cases, 
which will be designated b.  Descriptive analyses of disease-specific, healthcare system specific and 
overall yearly completeness of communicable disease reporting will be expressed as the proportion of 
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the diseased patients identified with ICD-9-CM diagnostic codes that were reported to the State 
Health Department’s communicable disease surveillance system, that is, the completeness proportion 
= a / (a+b).   
Figure 4.  Study Population Derivation 
  
 
a. Logit Transformation 
Logit transformations (i.e., ln a/b) were used to obtain normally distributed data for the odds of 
reporting where a= reported cases, b=not reported cases.   This transformation yields the following 
formulas for reporting completeness proportion, odds, logit and variance of the logit, 
reporting completeness proportion = a / (a+b)  
reporting completeness odds = a / b  
reporting completeness logit = ln (a / b)   
variance of reporting completeness logit= (1/a) + (1/b)  
 
After completion of the following analyses, the reporting logit values were converted to reporting pro-
portions using the following calculations: 
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reporting completeness logit = ln (a / b) 
reporting completeness odds = exp (ln (a / b))  
reporting completeness proportion = ( odds / odds + 1) 
  
b. Continuity Corrections 
 
For reporting proportions where a, the number of reported cases, is equal to zero,  smoothing 
methods based on those proposed by Sweeting et al were used in order to derive empirical continuity 
corrections for estimating reporting proportions and uncertainty intervals [75].   The following method 
was used, 
 
where,  
Ω is the pooled logit of all non-zero (a / b) case data weighted by the inverse variance of logit. 
 
Ω =  ∑  ln (a / b) / [(1 / a)+(1 / b)] 
 
And, 
the continuity corrected reported cases = a + (0.005*Ω)  
the continuity corrected unreported cases = b+ [0.005*(1- Ω)]  
2. Hierarchical Semi-Bayesian Regression Methods for Improved Precision 
Bayesian methods have been recommended for situations in which multiple comparisons are 
made [71, 76] and previously have been employed using disease prevalence data (e.g., toxoplasmo-
sis in El Salvador) [71].  Witte proposes using SAS IML code to conduct two stage hierarchical model-
ing for semi-Bayesian analyses to correct overestimates of observed variance [77].   This procedure 
serves to shrink unstable estimates towards the mean of the ensemble of estimates.  The degree to 
which estimates are shrunk is proportional to the precision of the estimate (measured in the first-
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stage model) and a prespecified variance (tau2). The resulting group of shrunken estimates should 
then have a distribution with a variance less than the variance of the distribution of conventional esti-
mates, and this lower variance will outweigh any bias introduced by the shifts [78].  
In the first stage of our hierarchical regression model, the continuity corrected logit of disease 
reporting completeness odds (reported/not reported) is regressed on each specific disease.  This first 
stage model produces the conventional maximum likelihood coefficient and covariance matrix esti-
mates.  The second stage model regresses the disease specific maximum likelihood coefficients from 
the first stage model on a model which contains a matrix of variables believed to determine the mag-
nitude of, or explain some variability between, the individual disease reporting completeness propor-
tions.  This matrix is often termed a Z-matrix or an exchangeability matrix.  The description of the Z-
matrix and the specific values are shown in Tables 6 and 7, respectively.  Each exchangeable set of 
diseases shares information to estimate the final adjusted beta coefficients and standard errors. 
 
Table 6.  Description of Exchangeability (Z-matrix) for Disease-Specific Reporting Completeness 
Title Category Description Hypothesis 
Time for Reporting 
 
Is the disease designated to be 
reported within 24 hours or 7 
days? 
Diseases required to be reported within 24 
hours are more severe, have more public 
health impact, therefore may be more 
likely to be reported 
Reportable by lab 
 
Is the disease required to be 
reported by the laboratory? 
Diseases that are required to be reported 
by the laboratory in addition to a healthcare 
provider may be more likely to be reported 
Serology Lab for Reporting  
Does the case definition for the 
disease require serology lab 
tests to confirm the disease? 
Serology test results usually require multi-
ple tests separated by 2-3 weeks for correct 
interpretation and these diseases may be 
less likely to be reported 
Person-to-Person Transmis-
sion 
Is the disease transmitted per-
son-to-person? 
Healthcare providers’ perception of the 
transmissibility of the disease may make 
these diseases more likely to be reported 
Category A Bioterrorism Agent 
Is the disease caused by a CDC 
classified category A bioterror-
ism agent? 
Healthcare providers’ perception of the 
severity of the disease may make these 
diseases more likely to be reported 
Arthropod borne Is the disease arthropod borne? 
Healthcare providers’ perception of the 
transmissibility of the disease may make 
these diseases less likely to be reported 
Food/ 
Waterborne 
 
Is the disease transmitted by 
food/water? 
Healthcare providers perception’ of the 
transmissibility of the disease may make 
these diseases more likely to be reported 
Aerosol/Droplet Transmission Is the disease transmitted by 
aerosol or droplet particles? 
Healthcare providers’ perception of the 
transmissibility of the disease may make 
these diseases more likely to be reported 
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Table 7.  Specific Values for the Exchangeability (Z-matrix) for Disease-Specific Reporting Completeness 
Disease 
Time for 
Report-
ing 
Reportable 
by Lab 
Serology 
Lab for 
Reporting 
Person-to-
Person 
Transmiss-
ion 
Category A 
Bioterrorism 
Agent 
Arthropod 
borne  
Food/ 
Waterborne 
Aerosol/droplet  
Transmission 
Anthrax 24 hours Yes No Yes Yes No Yes Yes 
Arboviral Encephali-
tis 7 days Yes Yes No No Yes No No 
Botulism 24 hours Yes No No Yes No Yes No 
Brucellosis 7 days Yes No No No No Yes Yes 
Campylobacteriosis 24 hours Yes No Yes No No Yes No 
Cholera 24 hours Yes No Yes No No Yes No 
Creutzfeldt-Jakob 
Disease 7 days No No Yes No No Yes No 
Cryptosporidiosis 24 hours Yes No Yes No No Yes No 
Cyclosporiasis 24 hours Yes No Yes No No Yes No 
Dengue 7 days Yes Yes No No Yes No No 
Diphtheria 24 hours Yes No Yes No No No Yes 
E.coli O157:H7 24 hours Yes No Yes No No Yes No 
Foodborne Disease, 
Staphylococcal 24 hours No No No No No Yes No 
Granulocytic Ehr-
lichiosis 7 days Yes Yes No No Yes No No 
Hantavirus 7 days Yes Yes No No Yes No Yes 
Hemolytic Uremic 
Syndrome 24 hours No No No No No No No 
Hemophilus influen-
zae, invasive dis-
ease 
24 hours Yes No Yes No No No Yes 
Hepatitis A, acute 24 hours Yes No Yes No No Yes No 
Legionellosis 7 days Yes No No No No No Yes 
Leptospirosis 7 days Yes No No No No Yes Yes 
Listeriosis 24 hours Yes No Yes No No Yes No 
Lyme Disease 7 days Yes No No No Yes No No 
Malaria 7 days Yes No No No Yes No No 
Measles 24 hours Yes Yes Yes No No No Yes 
Meningococcal men-
ingitis 24 hours Yes No Yes No No No Yes 
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Disease 
Time for 
Report-
ing 
Reportable 
by Lab 
Serology 
Lab for 
Reporting 
Person-to-
Person 
Transmiss-
ion 
Category A 
Bioterrorism 
Agent 
Arthropod 
borne  
Food/ 
Waterborne 
Aerosol/droplet  
Transmission 
Monocytic Ehrlicho-
sis 7 days Yes Yes No No Yes No No 
Mumps 7 days Yes Yes Yes No No No Yes 
Plague 24 hours Yes No Yes Yes No No Yes 
Pneumococcal men-
ingitis 7 days Yes No No No No No Yes 
Poliovirus 24 hours Yes No Yes No No Yes No 
Psittacosis 7 days Yes Yes No No No No Yes 
Q fever 7 days Yes Yes No No No Yes Yes 
Rabies, human 24 hours Yes No No No No No No 
RMSF 7 days Yes Yes No No Yes No No 
Rubella  24 hours Yes Yes Yes No No No Yes 
Rubella Congenital 
Syndrome 7 days Yes Yes Yes No No No Yes 
Salmonellosis 24 hours Yes No Yes No No Yes No 
SARS 24 hours No No Yes No No No Yes 
Shigellosis 24 hours Yes No Yes No No Yes No 
Smallpox 24 hours Yes No Yes Yes No No Yes 
Streptococcal Infec-
tion, group A, inva-
sive 
7 days Yes No No No No No No 
Tetanus 7 days No No No No No No No 
Toxic Shock Syn-
drome 7 days No No No No No No No 
Trichinosis 7 days Yes No No No No Yes No 
Tuberculosis 24 hours Yes No Yes No No No Yes 
Tularemia 24 hours Yes No No Yes Yes Yes No 
Typhoid Fever 24 hours No No Yes No No Yes No 
Typhus, epidemic 7 days No No No No Yes No No 
Vaccinia 24 hours Yes No Yes No No No Yes 
Vibrio vulnificus 24 hours Yes No No No No Yes No 
Vibrio, other 24 hours Yes No No No No Yes No 
Whooping Cough 
(Pertussis) 24 hours Yes Yes Yes No No No Yes 
Yellow Fever 7 days Yes Yes No No Yes No No 
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In addition, a prespecified variance (tau2) is used in the second stage hierarchical regression.  
This variance is chosen to incorporate some prior knowledge— maximum likelihood estimates which 
have previously been the standard in many fields are just a special case of Bayesian analysis where 
the variance = ∞ and proportion estimates range from 0-100%.  However, even by pre-specifying that 
the likely 95% confidence interval range is from 7-85% rather than 0-100% we are able to obtain 
more precise estimates.   Different values of tau2 (high tau2 with 95% CI of 2.2-95%, medium tau2 with 
95% CI of 7-85% low tau2 with 95% CI of 12.9-75%, zero tau2 with 95% CI of 35-45%) were tested in 
the sensitivity analysis.  In addition, a sensitivity analysis was conducted on the prior covariates in the 
Z matrix.  Comparisons were made between a model with all prior covariates, no prior covariates and 
each prior covariate alone.  Resultant beta coefficients and standard errors for the odds of reporting 
were exponentiated and then converted back to proportions using the equation: proportion = 
odds/(odds+1) to obtain adjusted estimates of proportions and 95% uncertainty limits (UI). 
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3. Logistic Regression for Yearly and Healthcare System Specific Disease Reporting 
Completeness Proportions 
Binomial logistic regression models were utilized to estimate the odds of reporting completeness 
by year for the three healthcare systems with complete data and by healthcare system for the time 
period 2000-2006.  Resultant beta coefficients and standard errors for the odds of reporting were ex-
ponentiated and then converted back to proportions using the equation: proportion = odds/(odds+1) 
to obtain estimates of proportions and 95% confidence intervals.  A generalized linear regression 
model was used to fit a linear trend line to the graph of reporting proportions by year and these lines 
were described by their slope and 95% confidence intervals for the slope coefficient.  Covariates in-
cluded for the binomial logistic regression model for healthcare system model included details on how 
many dedicated staff there are for reporting communicable diseases (i.e., physician, laboratory, infec-
tion control and/or PHE).  The data on dedicated staff was determined based on a survey completed 
by all PHE hospitals that consisted of the following four questions.  The survey tool is presented be-
low and results of this survey are summarized in Table 8. 
1.  In your position as the PHE, are you responsible for the actual reporting of new communica-
ble disease cases to the health department? (If yes, go to Q#2) (If no, skip to Q#3) 
2.  If you are currently responsible for reporting, was someone in your facility’s infection con-
trol/hospital epidemiology department responsible before the PHE program began? (Go to 
Q#4) 
3.  If you are not currently responsible for the reporting, is someone else in your facility’s infec-
tion control/hospital epidemiology department responsible for the actual reporting of commu-
nicable diseases to the health department? (If yes, go to Q#4) (If no, done) 
4.  If you or infection control/hospital epidemiology do the reporting, are your physicians and 
laboratories still expected to report too? 
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Table 8.  Healthcare System Dedicated Personnel for Communicable Disease Reporting 
Healthcare System Public Health Epidemiologist Infection Control  Physician and or Lab  
A Yes Yes Yes 
B No No Yes 
C Yes No Yes 
D Yes Yes No 
E No Yes Yes 
F No No Yes 
G No No Yes 
H Yes No Yes 
4. Validation Study Measurements 
Results of the validation study were summarized as positive predictive value proportions.  Dis-
ease-specific positive predictive values (PPV) were calculated based on the number of ICD-9-CM 
disease cases that are determined to be true communicable disease cases based on CDC case defi-
nitions, that is the true positives, divided by the total number of reviewed diseased patients identified 
with ICD-9-CM codes which includes both true positives, TP,  and false positives, FP (Table 9). 
Table 9.  Validation Study Design 
  
CDC Case Classification 
Case Not a Case 
ICD-9-CM Code for 
Communicable Disease 
Disease True Positive (TP) False Positive (FP) 
No Disease False Negative (FN) True Negative (TN) 
 
The estimated positive predictive value for each reporting strata of a disease (i.e., reported, not re-
ported) was combined to obtain an overall disease specific PPV and variance using the sampling 
weights from each strata using the following formulas.  The same procedure was used to combine the 
disease-specific PPVs across each healthcare system strata.   
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where,  
K=number of strata 
nk = size of sample from stratum k 
N = size of all strata 
Wk = nk/N = the stratum weight 
Sk2 = unbiased estimated variance of proportion= pk *qk / (nk - 1) 
pk= estimated positive predictive value 
qk= 1- pk 
Logit transformations and continuity corrections were applied to the positive predictive value of 
ICD-9-CM codes for communicable disease surveillance as previously described.  In addition, hierar-
chical semi-Bayesian regression methods for improved precision of the disease-specific PPV were 
utilized as previously described.  The description of the Z-matrix for the disease-specific PPVs and 
the specific values are shown in Tables 10 and 11, respectively. 
We chose a tau2 value of 1.68 that specified a 95% confidence interval range from 10-95% 
rather than 0-100%.   Different values of tau2 (high tau2 with 95% CI of 2-99%, low tau2 with 95% CI of 
49-70%, zero tau2 with 95% CI of 57-63%) were tested.  In addition, a sensitivity analysis was con-
ducted on the prior covariates in the Z matrix.  Comparisons were made between a model with all 
prior covariates, no prior covariates and each prior covariate alone.  Resultant beta coefficients and 
standard errors for the odds of reporting were exponentiated and then converted back to proportions 
using the equation: proportion = odds/(odds+1) to obtain adjusted estimates of proportions and 95% 
uncertainty limits (UI).   
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Table 10.  Description of Exchangeability (Z-matrix) for Disease-Specific Positive Predictive Values 
Title Category Description Hypothesis 
Reportable by lab 
 
Is the disease required to 
be reported by the labora-
tory? 
Diseases that have diagnostic laboratory 
findings may be more likely to have an 
ICD-9-CM code consistent with CDC case 
definitions. 
Serology Lab for Reporting 
Does the case definition for 
the disease require serol-
ogy lab tests to confirm the 
disease? 
Diseases that have diagnostic laboratory 
findings may be more likely to have an 
ICD-9-CM code consistent with CDC case 
definitions. 
Rare Disease 
Is the disease relatively 
rare in North Carolina (<10 
cases per year)? 
Diseases that are relatively common are 
more likely to have an correct assignment 
of an ICD-9-CM code. 
 
 
Table 11.  Specific Values for the Exchangeability Matrix (Z-matrix) for Disease-Specific Positive Pre-
dictive Values 
Disease Reportable by Lab Serology Lab for Reporting Rare disease 
Arboviral Encephalitis Yes Yes No 
Brucellosis Yes No Yes 
Campylobacteriosis Yes No No 
Cholera Yes No Yes 
Creutzfeldt-Jakob Disease No No Yes 
Cryptosporidiosis Yes No No 
Cyclosporiasis Yes No Yes 
Dengue Yes Yes Yes 
Diptheria No Yes Yes 
E.coli O157:H7 Yes No No 
Foodborne Disease, Staphylococcal No No No 
Granulocytic Ehrlichiosis Yes Yes Yes 
Hantavirus Yes Yes Yes 
Hemophilus influenzae, invasive disease Yes No No 
Hepatitis A, acute Yes No No 
Hemolytic Uremic Syndrome No No Yes 
Legionellosis Yes No No 
Leptospirosis Yes No Yes 
Listeriosis Yes No No 
Lyme Disease Yes No No 
Malaria Yes No No 
Measles Yes Yes Yes 
Meningococcal meningitis Yes No No 
 44 
 
Disease Reportable by Lab Serology Lab for Reporting Rare disease 
Monocytic Ehrlichosis Yes Yes No 
Mumps Yes Yes Yes 
Plague Yes No Yes 
Pneumococcal meningitis Yes No No 
Poliovirus Yes No Yes 
Psittacosis Yes Yes Yes 
Q fever Yes Yes Yes 
Rabies, human Yes No Yes 
RMSF Yes Yes No 
Rubella Congenital Syndrome Yes Yes Yes 
Rubella  Yes Yes Yes 
Salmonellosis Yes No No 
Shigellosis Yes No No 
Smallpox Yes No Yes 
Streptococcal Infection, group A, invasive Yes No No 
Tetanus No No Yes 
Toxic Shock Syndrome No No Yes 
Trichinosis Yes No Yes 
Tuberculosis Yes No No 
Tularemia Yes No Yes 
Typhoid, acute No No Yes 
Vaccinia Yes No Yes 
Vibrio infection, other Yes No Yes 
Whooping Cough (Pertussis) Yes Yes No 
 
5. Limitations of Validation Study  
Ideally, the validation study would have provided a measure of both positive predictive value and 
sensitivity of ICD-9-CM codes for CDC communicable disease case definitions.  With both of these of 
these estimates and using Bayes Theorem, the disease reporting completeness proportions based on 
ICD-9-CM codes, that is P(R|I), could be adjusted so that they were estimates of the proportion of 
CDC defined cases who were reported to NC DHHS, that is, P(R|C).  The formula for this adjustment 
is presented below. 
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Where, 
R =Reported to the NC DHHS surveillance system 
C =Meets the CDC case definition 
I =Assigned an ICD-9-CM code for a communicable disease 
 
P(R|C) = P(C|R) P(R) 
        P(C) 
 
  = P(C|R) P(R|I) P(I) 
             P(C)     P(I|R)  
 
  = P(C|R) P(I|C) P(R|I) P(I) 
        P(C|I) P(I)  P(I|R)  
 
  = P(C|R) P(I|C) P(R|I)  
         P(I|R) P(C|I) 
 
With the following estimates, 
P(R|I)=completeness proportions as estimated in this study 
P(C|I)= positive predictive values estimated in this study 
P(C|R)=1, because all diseases reported are required to meet the CDC case definition 
P(I|R)= unknown 
P(I|C)= unknown 
 
This study’s aims did not include estimates of P(I|R) and P(I|C).  These estimates can be further de-
scribed (Figure 5). 
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Figure 5.  2 x 8 Table of Unmeasured Variables Required for Adjustment 
 
 
 
  
 
 
 
 
 
 
 
 
 
Where,  
P(I|R) = (A1+C1)/(A1+C1+A2+C2) = (A1)/(A1+A2), since C1 and C2=0 because all diseases reported 
are required to meet the CDC case definition 
and 
P(I|C)=  (A1+B1)/(A1+B1+A2+B2) 
 
An additional study would need to be designed using an alternate data source such as labora-
tory records or as a true gold standard, complete medical record chart review to obtain estimates of 
A2 and B2 for each disease under study.  Once these estimates have been obtained, communicable 
disease surveillance and study evaluations using ICD-9-CM codes can be adjusted to estimate cases 
of communicable diseases as we would like here to appropriately adjust P(R|I) to more accurately 
represent P(R|C).   
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H. Quality Assurance 
The major logistical challenge in this study was to obtain 10 years of data from 8 different 
healthcare systems.  Fortunately, the Public Health Epidemiologist (PHE) network facilitated this 
process as each PHE was committed to participating in this study and are employees of their respec-
tive healthcare systems.  Each PHE requested data from their healthcare system’s medical records 
department using standardized specifications outlined by the Principal Investigator and PHE Program 
Director.  Ongoing training on these data specifications was provided to the PHEs at training ses-
sions, individual meetings and conference calls.  Data from the NC DHHS was requested using writ-
ten data specifications and obtained from each Branch (i.e., General Communicable Diseases, 
HIV/STDs, TB) in person by the Principal Investigator.  Training on the methods for the chart review 
involved in validation study was provided to the PHE co-investigators in a written protocol, on confer-
ence calls and at training sessions.  The standardized data specifications, training sessions for PHE 
co-investigators and written study protocols helped to assure the quality and consistency of the data 
collected for analysis.   
I. Human Subjects Research 
Institutional review board (IRB) approval was obtained at each participating healthcare institu-
tion.  In addition, a Grant of Public Health Authority has been issued from North Carolina’s Depart-
ment of Public Health to the principal investigator at the sponsoring institution, Emily E. Vavalle of 
UNC-CH School of Public Health and UNC Health Care System.   
This retrospective cohort study included a review of hospital medical records and surveillance 
records for all eligible patients assigned an ICD-9-CM code for a communicable disease; these pa-
tients did not exclude special populations such as pregnant women, children and prisoners.  How-
ever, patients were not contacted during the course of this study, so no additional precautions were 
necessary when including these vulnerable populations.  Certain protected health information was 
obtained on each patient in order to conduct this study; these included name, date of birth, and social 
security numbers.  The risks to the study subjects were minimal and the primary concern in this study 
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was maintaining the confidentiality of the data.  Data confidentiality was maintained by restricting ac-
cess of data to study investigators, storing hard copies of data in locked file cabinets in locked offices, 
and storing electronic copies of data on password protected, encrypted computers in locked offices.  
In addition, after completion of matching the hospital and surveillance databases and data analysis, 
all protected health information will be destroyed.  Study subjects will not directly benefit from this re-
search; however, results from this study will be disseminated and used to improve North Carolina’s 
public health surveillance system.   
Because thousands of patients were included in this retrospective cohort study using existing 
medical records and public health surveillance data, informed consent of subjects was impractical 
due to both the size of the study and the retrospective nature of the data collection.  Therefore, we 
were granted a waiver of the informed consent process and for the Health Insurance Portability and 
Accountability Act (HIPAA) required documentation for access to healthcare records of the case-
patients at each participating healthcare system per each institution’s policies. 
 IV. Chapter 4: Manuscript “Completeness of Communicable Disease Reporting for 10 
Years and For More Than 50 Diseases in Eight North Carolina Healthcare Systems”  
A. Abstract  
Context:  Communicable disease surveillance is the key method by which states measure endemic 
disease incidence in the community, recognize disease outbreaks, assess the effectiveness of pre-
vention and control measures, allocate public health resources, and further understand the epidemi-
ology of new and/or emerging pathogens. Despite the widespread usage of surveillance data, the 
reporting completeness of this system has never been comprehensively assessed. This is the most 
comprehensive study to date of reporting completeness with an analysis of over 50 diseases and 
conditions reported by eight healthcare systems across the State of North Carolina during a 10 year 
time period. 
 
Objective:  To describe changes in reporting completeness over time, estimate disease-specific re-
porting completeness, and examine the variability in reporting between healthcare systems. 
 
Design: A retrospective cohort study was conducted for the years 1995-1997 and 2000-2006. 
 
Setting: Eight acute care healthcare systems in North Carolina which represent 32% of all inpatient 
visits and 23% of all outpatient visits in NC. 
 
Participants: All inpatients and outpatients who were assigned an ICD-9-CM diagnosis code for a 
state required reportable communicable disease. 
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Main Outcome Measure: Semi-Bayesian adjusted disease-specific reporting proportions with 95% 
uncertainty intervals. 
 
Results:  In general reporting completeness improved over time. Disease-specific reporting com-
pleteness proportions ranged from 0-82%, but were generally very low.  The completeness of report-
ing varied among the healthcare systems from 2-30%. 
 
Conclusions:  Disease reporting completeness based on healthcare facility assigned ICD-9-CM codes 
was very low even for diseases with great public health importance and opportunity for interventions 
to prevent person-to-person transmission (e.g., meningococcal meningitis 21.2%).  In addition, report-
ing completeness varied by healthcare system which may be due to healthcare system-specific poli-
cies that designate additional person(s) to be responsible for disease reporting, and reporting com-
pleteness has increased over time which likely is explained by regulatory and programmatic changes, 
but it remains very low. 
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B. Introduction 
Surveillance has been the cornerstone of public health since Congress authorized the Public 
Health Service to collect morbidity data for cholera, smallpox, plague and yellow fever in 1878.  Cur-
rently, states conduct surveillance of communicable diseases following guidelines from the Centers 
for Disease Control and Prevention (CDC) and the Council for State and Territorial Epidemiologists 
(CSTE).  The current list of nationally notifiable communicable diseases has expanded to over 60 
diseases to include vaccine-preventable diseases (e.g., pertussis, measles), emerging infectious dis-
eases (e.g., SARS, West Nile Virus encephalitis), foodborne diseases (e.g., Shiga toxin-producing E. 
coli, salmonella), sexually transmitted diseases (e.g., syphilis, HIV), as well as aerosol and droplet 
transmitted diseases (e.g., tuberculosis, meningococcal meningitis).  Surveillance on these epidemi-
ologically important diseases provides critical information both to clinicians and public health officials 
as it is used for the measurement of disease incidence in communities, recognition of disease out-
breaks, assessment of prevention and control measure effectiveness, allocation of public health re-
sources, and further understanding the epidemiology of new and emerging pathogens [3].   
 Like all states, North Carolina (NC) state laws and rules require communicable disease report-
ing [5, 79, 80] and relies on physicians and laboratories complying with the mandate to report dis-
eases and laboratory results indicative of diseases considered a threat to the public health.  During 
this study’s time period, disease reports in NC consisted of paper communicable disease report forms 
and contained demographic, clinical and risk factor data for the case-patient.  These reports are re-
quired to be submitted to the health department within a specified period of time (i.e., immediately, 
within 24 hours, or within 7 days) depending on the disease.  An important change to NC Department 
of Health and Human Service’s (NC DHHS) communicable disease surveillance system occurred in 
September of 1998 when the state administrative code was amended to require that persons in 
charge of diagnostic laboratories report positive laboratory results for most diseases already report-
able by physicians[79].  This dual reporting mechanism was intended to improve completeness, time-
 52 
 
liness and accuracy of surveillance.  More recently NC’s surveillance efforts have also expanded with 
the introduction of 7 regional public health teams and 11 hospital-based public health epidemiologists 
in 2002.   
Despite the widespread use of these surveillance data, the systematic collection of these data 
via mandatory physician and laboratory reporting has never been extensively evaluated.  To date, 
only two evaluations have examined reporting proportions for more than five diseases [11] [12].  Pre-
vious studies examining completeness of disease reporting have differed considerably by size of 
geographic region (e.g., clinics at a single university to multiple states), range of study time period 
(e.g., several months to several years), heterogeneity of reporting systems (e.g., healthcare provider-
based passive reporting versus both healthcare provider- and laboratory-based passive reporting), 
and various patient ascertainment methods (e.g., laboratory records, billing records, active surveil-
lance, death certificates) rendering the results of these studies difficult to compare or aggregate.  
Therefore, we have undertaken the most comprehensive study of reporting completeness to date with 
an analysis of over 50 reportable diseases and conditions in selected healthcare systems across 
North Carolina during a 10 year time period in order estimate disease-specific reporting proportions, 
describe changes to reporting over time, and examine the variability of reporting completeness be-
tween healthcare facilities.   
C. Methods 
A retrospective cohort study was conducted at eight large North Carolina (NC) non-federal acute 
care healthcare systems that make up 32% of all inpatient visits and 23% of all outpatient visits in NC 
[65].  These healthcare systems ranged from 581 to 1324 site-licensed beds, spanned the Eastern 
Coastal, Central Piedmont, and Western Mountain regions of the state, and were selected from a 
network of 11 healthcare systems staffed with hospital-based Public Health Epidemiologists (PHE).   
The study cohort was defined as all inpatients and outpatients at the eight healthcare systems who 
were assigned a discharge diagnostic code (ICD-9-CM) that corresponds with a reportable communi-
cable diseases during a ten year study time period (1995-1997, 2000-2006). The years 1998-1999 
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were excluded from the study because this period marked the transition when the state law changed 
to include a reporting requirement for laboratories.   
Diseases were excluded if they were chronic infectious diseases thus resulting in a recurring as-
signment of ICD-9-CM code (e.g., HIV, Hepatitis B carrier), if no specific ICD-9-CM code was avail-
able (e.g., viral hemorrhagic fever), or if the NC DHHS did not record patient identifiers in their surveil-
lance database during the entire study time period (e.g., syphilis, gonorrhea, chlamydia).  Appendix 1 
contains a list of diseases and codes used for this study.  Approval for the study was granted by the 
Institutional Review Boards of all healthcare systems as well as the NC Division of Public Health.   
The cohort of patients assigned ICD-9-CM diagnostic codes by the healthcare systems for a re-
portable communicable disease were matched to the NC DHHS reported case-patients using a 
unique identifier created by either social security number, or a combination of the first two letters of 
the last name, first letter of the first name, date of birth, and a 2 digit disease code.  Repeat patient 
visits within a 31 day window for the same disease were enumerated and only the first visit was re-
tained with the exception of tuberculosis which had 365 day window.   Hepatitis A and paralytic polio 
were restricted to the first visit since they can only be acquired once in a lifetime.  Patients who had 
dates of reporting to the NC DHHS prior to the date of diagnosis at the healthcare system were ex-
cluded as they represented cases which had already been reported.  
Unadjusted disease-specific reporting completeness proportions were calculated by dividing the 
number of case-patients that were reported to NC DHHS by the total number of patients identified in 
the healthcare systems who were assigned an ICD-9-CM diagnostic code for a reportable disease.  In 
addition, completeness proportions were estimated by year (1995-1997, 2000-2006) for the three 
healthcare systems that had complete data available for all 10 years and generalized linear regres-
sion models were fit to examine the time trends.  For the years 2000-2006, reporting completeness 
proportions and 95% confidence intervals were estimated for each healthcare system using a bino-
mial logistic regression model that included as covariates whether specific healthcare system person-
nel were designated for disease reporting. 
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For disease-specific reporting completeness proportions, empirical continuity corrections were 
used when no patients were reported for a disease [75].  In addition, adjusted completeness propor-
tions and 95% uncertainty intervals were calculated using semi-Bayesian analysis [77] as recom-
mended to reduce the mean squared error when an ensemble of measures are estimated [71].   This 
semi-Bayesian hierarchical regression analysis utilizes prior covariates that help to explain the mean 
of the ensemble of estimates as well as a specified prior variance (tau2) of the distribution.  Traditional 
maximum likelihood estimates (i.e., unadjusted estimates as presented here) can be viewed as a 
special case of semi-Bayesian analysis in which the prior variance is infinite.  By specifying even a 
moderately informative prior variance such as a tau2 indicating that 95% of all completeness propor-
tions lie between 7.3% and 85%, an appreciable reduction in the overall mean squared error can be 
expected with a shift in the point estimate and a narrowing of the 95% uncertainty interval for each 
completeness proportion, with the relative degree of narrowing being greater for diseases with less 
information.   
A sensitivity analysis was conducted on the specified prior variance (tau2) using high, medium 
and low tau2 values that assumed that 95% of the completeness proportions were within the following 
ranges: [2.2, 95%], [7.3, 85%], [12.9, 75%].  Sensitivity analyses were also conducted on the inclu-
sion or exclusion of prior covariates which were the time frame for reporting the disease (i.e., 24 
hours vs. 7 days), whether or not the disease had a reportable laboratory result, whether or not the 
disease had reportable serology test results, whether the disease is classified as a CDC category A 
bioterrorism agent, and the mode of transmission of the disease (person-to-person, arthropod-borne, 
food/water-borne, droplet/aerosol). 
D. Results 
Unadjusted and adjusted disease specific reporting completeness proportions for 2000-2006 
with 95% confidence intervals and uncertainty intervals, respectively, are summarized in Table 12.  
The adjusted disease specific reporting completeness proportions ranged from 0-82.0% and almost 
all diseases (49/53) had reporting completeness proportions less than 50%.  Eleven diseases ac-
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counted for 90% of disease reporting: salmonellosis, tuberculosis, meningococcal disease, Rocky 
Mountain spotted fever, campylobacteriosis, shigellosis, acute hepatitis A, pneumococcal meningitis, 
legionellosis,malaria and Hemophilus influenzae,invasive disease.  Some unexpected diseases had 
patients identified with an ICD-9-CM; for example, anthrax had 14 patients identified, paralytic polio 
had 32 patients identified, human rabies had 12 patients identified, and smallpox had 9 patients iden-
tified.  The most dramatic adjustments in the unadjusted to adjusted point estimates were noted for 
staphylococcal foodborne disease, Vibrio vulnificus, and other Vibrio infections with ~80% change in 
point estimate; however, wide uncertainty intervals also reflect the imprecision in these estimates. 
Figure 5 displays the overall reporting proportions by year for the two time periods, 1995-1997, 
when only physicians were required to report most diseases and 2000-2006, when both laboratories 
and physicians were required to report.  Reporting increased significantly in the second time period, 
but was still very low overall with the linear trend line slope approximately equal to 0 and the intercept 
equal to 10.2%.  Figure 6 displays the reporting proportions by healthcare system for the years 2000-
2006.  The completeness proportions ranged from 1.8-29.7% with an overall median proportion of 
8.0%.  The covariates that described whether each healthcare system designated individuals to re-
port had no effect on a healthcare system’s reporting proportion. 
The sensitivity analysis of the tau2 values showed that the point estimates and uncertainty inter-
vals (UI) were relatively insensitive to dramatic changes in tau2; for example, for meningococcal men-
ingitis with a low tau, the reporting proportion and 95% UI was estimated as: 21% (16-28%), with a 
medium tau, 22% (16-28%); and with a high tau, 22% (16-29%), and the sensitivity analyses examin-
ing the use of prior covariates were shown only to have effects on the reporting proportion and 95% 
UI for diseases with sparse data; for example, cholera with all prior covariates 22% (3-74%), no prior 
covariates 10% (1-51%), time covariate alone 50% (10-89%).   
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Table 12.  Disease-Specific Reporting Completeness Proportions in NC (2000-2006) 
Communicable Disease 
Number 
of 
Cases 
Re-
ported 
to NC 
DHHS 
Number of 
Patients 
Identified by 
ICD-9-CM 
Code for 
Reportable 
Disease 
Unadjusted 
Reporting 
Completeness 
Proportion 
Lower 
95% CI 
Upper 
95% CI 
Semi-Bayesian 
Adjusted Re-
porting Com-
pleteness Pro-
portion 
Lower 
95% UI 
Upper 
95% UI 
Anthrax 0 14 0.01% 0.00% 100.00% 0.00% 0.00% 100.00% 
Arboviral Encephalitis 0 18 0.00% 0.00% 100.00% 8.67% 0.80% 52.77% 
Botulism 0 4 0.02% 0.00% 100.00% 0.08% 0.00% 100.00% 
Brucellosis 0 33 0.00% 0.00% 100.00% 23.02% 1.36% 86.62% 
Campylobacteriosis 39 97 40.21% 30.94% 50.22% 39.96% 30.82% 49.85% 
Cholera 0 6 0.01% 0.00% 100.00% 18.58% 2.24% 69.41% 
CJD/vCJD 0 32 0.00% 0.00% 100.00% 0.87% 0.03% 22.97% 
Cryptosporidiosis 10 84 11.90% 6.53% 20.73% 12.59% 7.07% 21.42% 
Cyclosporiasis 0 3 0.03% 0.00% 100.00% 18.59% 2.25% 69.42% 
Dengue 4 25 16.00% 6.14% 35.69% 14.48% 5.92% 31.31% 
Diphtheria 0 5 0.02% 0.00% 100.00% 8.28% 0.82% 49.70% 
E .coli, Shiga-Toxin Producing 1 3 33.33% 4.34% 84.65% 24.67% 5.82% 63.45% 
Foodborne Disease: Staphy-
loccocal 0 14 0.01% 0.00% 100.00% 74.74% 16.74% 97.76% 
Granulocytic Ehrlichiosis 0 67 0.00% 0.00% 100.00% 8.66% 0.80% 52.74% 
Hantavirus Infection 0 3 0.03% 0.00% 100.00% 10.10% 0.62% 67.06% 
Hemolytic Uremic Syndrome 5 429 1.17% 0.49% 2.77% 2.20% 0.99% 4.84% 
Hemophilus Influenzae, Inva-
sive Disease 14 1086 1.29% 0.76% 2.16% 1.45% 0.87% 2.42% 
Hepatitis A 27 866 3.12% 2.15% 4.51% 3.34% 2.31% 4.81% 
Legionellosis 24 98 24.49% 16.99% 33.95% 24.04% 16.72% 33.27% 
Leptospirosis 0 33 0.00% 0.00% 100.00% 23.02% 1.36% 86.62% 
Listeriosis 10 64 15.63% 8.62% 26.67% 16.14% 9.12% 26.95% 
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Communicable Disease 
Number 
of 
Cases 
Re-
ported 
to NC 
DHHS 
Number of 
Patients 
Identified by 
ICD-9-CM 
Code for 
Reportable 
Disease 
Unadjusted 
Reporting 
Completeness 
Proportion 
Lower 
95% CI 
Upper 
95% CI 
Semi-Bayesian 
Adjusted Re-
porting Com-
pleteness Pro-
portion 
Lower 
95% UI 
Upper 
95% UI 
Lyme Disease 8 790 1.01% 0.51% 2.01% 1.18% 0.60% 2.30% 
Malaria 17 155 10.97% 6.93% 16.94% 10.71% 6.80% 16.47% 
Measles 0 14 0.01% 0.00% 100.00% 15.98% 1.41% 71.63% 
Meningococcal Disease 38 179 21.23% 15.85% 27.83% 21.19% 15.85% 27.73% 
Monocytic Ehrlichiosis 1 4 25.00% 3.35% 76.22% 14.84% 3.12% 48.52% 
Mumps 1 96 1.04% 0.15% 7.02% 1.07% 0.20% 5.49% 
Plague 0 28 0.00% 0.00% 100.00% 0.00% 0.00% 100.00% 
Pneumococcal Meningitis 20 191 10.47% 6.86% 15.67% 10.61% 6.99% 15.80% 
Polio, paralytic 0 32 0.00% 0.00% 100.00% 18.56% 2.24% 69.38% 
Psittacosis 0 21 0.00% 0.00% 100.00% 17.45% 1.57% 73.69% 
Q Fever 3 14 21.43% 7.07% 49.43% 25.68% 9.14% 54.28% 
Rabies, Human 0 12 0.01% 0.00% 100.00% 59.69% 8.00% 96.19% 
Rocky Mountain Spotted Fever 40 986 4.06% 2.99% 5.48% 4.19% 3.10% 5.66% 
Rubella 0 39 0.00% 0.00% 100.00% 15.97% 1.41% 71.61% 
Rubella Congenital Syndrome 0 10 0.01% 0.00% 100.00% 1.08% 0.07% 15.32% 
Salmonellosis 263 594 44.28% 40.33% 48.30% 44.82% 40.87% 48.83% 
SARS (Coronavirus Infection) 0 1 0.08% 0.00% 100.00% 5.71% 0.28% 56.27% 
Shigellosis 38 213 17.84% 13.26% 23.57% 18.17% 13.56% 23.93% 
Smallpox 0 9 0.01% 0.00% 100.00% 0.00% 0.00% 100.00% 
Streptococcal Infection, Group 
A, Invasive Disease 8 111 7.21% 3.65% 13.75% 7.40% 3.80% 13.92% 
Tetanus 1 20 5.00% 0.70% 28.22% 5.25% 1.09% 21.78% 
Toxic Shock Syndrome 4 142 2.82% 1.06% 7.26% 3.22% 1.28% 7.83% 
Trichinosis 0 23 0.00% 0.00% 100.00% 20.21% 1.82% 77.58% 
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Communicable Disease 
Number 
of 
Cases 
Re-
ported 
to NC 
DHHS 
Number of 
Patients 
Identified by 
ICD-9-CM 
Code for 
Reportable 
Disease 
Unadjusted 
Reporting 
Completeness 
Proportion 
Lower 
95% CI 
Upper 
95% CI 
Semi-Bayesian 
Adjusted Re-
porting Com-
pleteness Pro-
portion 
Lower 
95% UI 
Upper 
95% UI 
Tuberculosis 100 1439 6.95% 5.74% 8.38% 7.10% 5.87% 8.55% 
Tularemia 0 6 0.01% 0.00% 100.00% 0.04% 0.00% 100.00% 
Typhoid, acute 3 12 25.00% 8.28% 55.18% 21.57% 7.49% 48.30% 
Typhus, epidemic (louse-
borne) 0 2 0.04% 0.00% 100.00% 2.93% 0.12% 42.63% 
Vaccinia 0 13 0.01% 0.00% 100.00% 8.27% 0.82% 49.68% 
Vibrio Infection, Other 0 1 0.08% 0.00% 100.00% 81.58% 20.46% 98.71% 
Vibrio vulnificus 0 2 0.04% 0.00% 100.00% 81.57% 20.45% 98.71% 
Whooping Cough (Pertussis) 11 54 20.37% 11.65% 33.16% 20.31% 11.78% 32.72% 
Yellow Fever 0 3 0.03% 0.00% 100.00% 8.69% 0.80% 52.81% 
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Figure 5.  Reporting Completeness of Communicable Diseases in NC by Year with 95% 
Confidence Intervals 
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Figure 6.  Reporting Completeness of Communicable Diseases in NC Healthcare Systems from 
2000-2006 
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E. Comment 
The public health surveillance system in North Carolina in this study is similar to surveillance 
systems utilized nationwide, and although federal funding in addition to state and local budgets sup-
port the infrastructure and maintenance of these systems, they are rarely evaluated with respect to 
the completeness of the communicable disease data reported.  North Carolina’s population is ranked 
11th in the nation based on the 2000 Census, is the seventh largest state east of Mississippi river, 
and it is diverse enough to experience both exotic communicable diseases (e.g., malaria) as well as 
routine diseases (e.g., salmonellosis).  The size and population diversity allowed for a thorough 
evaluation of the completeness of many reportable communicable diseases that have rarely been 
evaluated in previous studies.  This study used a trained network of hospital-based Public Health 
Epidemiologists to gather and review data from existing medical records and existing surveillance 
databases.   
Disease-specific reporting completeness proportions were estimated to be very low and varied 
greatly based on disease.  There are several explanations for variations among disease reporting.  
First, clinicians may have the perception that some diseases have greater public health threat based 
on their communicability or morbidity and mortality (e.g., tuberculosis vs. salmonellosis).  Secondly, 
some diseases have relatively straightforward and primarily laboratory-based case definitions (e.g., 
stool culture positive for Salmonella with a clinically compatible illness) whereas others are more 
complex either requiring multiple laboratory results (e.g., four-fold increase between acute and conva-
lescent serology for Rocky Mountain spotted fever) or a combination of multiple clinical signs and 
symptoms without any specific laboratory result (e.g. toxic shock syndrome which requires the pres-
ence of at least four of the five symptoms: fever, rash, desquamation, hypotension, multisystem in-
volvement).  One clear pattern that emerged in our findings was that diseases with fewer clinical crite-
ria and laboratory-based case definitions tended to have higher reporting rates (e.g., salmonellosis 
44.8% vs. toxic shock syndrome 3.2%).  Laboratory-based case definitions ensure that there is a dual 
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reporting system (i.e., both laboratory and physician) and are more straight forward because they re-
quire less time reviewing medical records for clinical signs and symptoms.  This finding underscores 
the importance of the simplicity of case definitions, an important attribute in surveillance system de-
velopment and maintenance. 
Notably, we identified some patients by ICD-9-CM diagnostic codes for diseases known to be 
eliminated in the US (i.e., smallpox and polio).  Numerous previous studies which have evaluated re-
porting completeness have also utilized ICD-9-CM codes [11, 12, 27] as they are standard codes that 
can be queried relatively easily and should capture clinical cases of disease regardless of laboratory 
confirmation.  The accuracy of the ICD-9-CM codes was a potential limitation in our study.  Therefore, 
we also conducted a validation study of the positive predictive values of ICD-9-CM codes for commu-
nicable disease surveillance using as the gold standard complete medical record review.  These re-
sults showed that for the majority of diseases with higher incidence and relatively straightforward di-
agnoses, the positive predictive values (PPV) were high (>80%) with the important exception of tu-
berculosis which had a PPV of 29% (Sickbert-Bennett EE, UNC Gillings School of Global Public 
Health, unpublished data).   For diseases with low PPVs, the estimates we present here are likely to 
be underestimates of the true reporting completeness.  An additional limitation of this study was that 
we were unable to assess the sensitivity of ICD-9-CM codes for communicable disease reporting.  
These estimates of sensitivity are required in order to make any adjustments to estimate the true re-
porting completeness proportion, that is how many cases were reported to NC DHHS divided by the 
total number of patients with a true reportable disease.  Quantification of both the sensitivity and posi-
tive predictive values of ICD-9-CM codes for communicable disease surveillance is essential in the 
interpretation of all ICD-9-CM data as these codes are used frequently for research studies and have 
been proposed as adjuncts to electronic, automated surveillance systems.  
We believe that the semi-Bayesian adjusted estimates offer improved overall accuracy and pre-
cision for our ensemble of reporting completeness estimates.  Based on our sensitivity analyses, we 
used a conservative value for our tau2 with a pre-specified distribution of 7.3%-85% as well as model 
that included all prior covariates.  We did note a dramatic shift in the reporting completeness propor-
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tions after semi-Bayesian adjustments for several diseases to include staphylococcal foodborne dis-
ease, Vibrio vulnificus, and other Vibrio infections.   This shift reflects both the imprecision in each 
disease’s measured estimates of reporting completeness and the shrinkage of their proportions to 
others in the same prior covariate group.  These three diseases have food/waterborne transmission 
and therefore their estimates are shrunk towards the mean of the food/waterborne transmission group 
of diseases which includes many of those with the highest reporting proportion (e.g., campylobacteri-
osis, salmonellosis).  This finding reinforces the importance of careful specification of prior covariates 
as well as judicious examination and interpretation of unadjusted and semi-Bayesian adjusted esti-
mates along with their precision.   
The reporting variation seen in Figure 6 among healthcare systems may be explained in part by 
healthcare systems’ internal policies which assign the responsibility for communicable disease report-
ing to the infection prevention department.  For example, the healthcare system with the highest re-
porting proportion (Healthcare System A) has hospital-based PHE and/or infection preventionists re-
sponsible for disease reporting while the healthcare system with the lowest reporting proportion 
(Healthcare System G) does not place any responsibility for reporting on the infection preventionists 
or hospital-based PHE.  However, adjusting for these healthcare system policies was not found to 
modify the healthcare system reporting completeness proportions.  Currently, the NC General Statute 
states that medical facilities may report [81] as opposed to physicians and persons in charge of labo-
ratories who shall report [51, 82].  Infection prevention departments typically receive laboratory data 
daily and routinely review medical records.  Because infection preventionists are well-trained on the 
application of case definitions and share disease prevention and control goals with the local health 
department, they can serve as partners to the local health department in assuring that diseases are 
reported and investigated appropriately.  However, with the existing requirements that physicians and 
laboratories report these diseases, consideration needs to be given to avoid redundancy in reporting 
into the surveillance system, which could cause reporting fatigue and the often mistaken assumption 
that someone else has reported the case-patient [47, 54].    
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The general trend of the yearly reporting completeness proportions suggests that disease report-
ing has improved over time yet remains very low.  Several notable changes have occurred in this time 
period to North Carolina’s surveillance system.  First, in 1998, the inclusion of laboratory mandated 
reporting served as a secondary reporting mechanism in addition to the already mandated physician 
based reporting.  Regional public health teams were established in 2002 in order to assist local health 
departments with outbreak investigations.  In 2003, a network of trained hospital-based Public Health 
Epidemiologists was initiated with their primary role as facilitators of disease reporting and/or investi-
gation of cases; also in 2003, a statewide syndromic surveillance system was created to assist in 
early case identification in the hospitals’ emergency departments.  Despite the positive effect these 
regulatory and programmatic changes likely has had on disease reporting, disease reporting remains 
low as is consistent with other passive reporting surveillance systems.   
More recently, automated alerting and data collection for case-patients with reportable diseases 
(e.g., a positive blood culture result with Gram-negative diplococci triggers an alert with case-patient 
contact information to infection preventionist and/or local health department staff) has been shown to 
increase reporting rates when applied to traditional passive surveillance systems [68] [13].  Although 
North Carolina, like many states, is in the process of developing an electronic disease surveillance 
system, the reporting of communicable diseases surveillance by physicians will still remain largely 
passive in that reporting will be accomplished by accessing a secure internet site and entering patient 
information.   
When health information exchange becomes a reality, public health surveillance can benefit sig-
nificantly by automating processes that currently rely on manual data entry. Automated disease re-
porting could be achieved by standardized queries directly from the electronic health records for key 
laboratory results (e.g., positive acid-fast bacillus sputum smear) and for simplified or proxy clinical 
case definitions using ICD-9-CM diagnosis codes or free-text admission diagnoses.  Upon recognition 
of these potential case-patients, automating surveillance data collection directly from electronic health 
records to populate data fields for basic patient demographics and laboratory results could also sig-
nificantly reduce administrative time for physicians and health department officials and expedite dis-
ease investigations.  This type of automated technology for electronic health records is consistent 
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with The American Recovery and Reinvestment Act of 2009 which authorizes the Centers for Medi-
care & Medicaid Services (CMS) to provide reimbursement incentives for healthcare entities who are 
“meaningful users” of certified electronic health record technology.  In fact, the recent draft recom-
mendations for defining “meaningful use” from the Health IT Policy Council to the National Coordina-
tor recommend that hospitals be capable of providing electronic submission of reportable lab results 
to public health agencies by 2011 [83].  Such an undertaking will require implementation of national 
laboratory reporting standards for hospitals and could only be accomplished with resource allocation 
and partnerships between health departments and health care systems.  The “meaningful use” of the 
electronic health record for automated case-finding and data collection will transition our current pub-
lic health surveillance system from passive to active and thereby overcome the major barriers to 
complete, accurate and timely communicable disease reporting and surveillance. 
 V. Chapter 5: Manuscript “Utility of ICD-9-CM Codes for Infectious Disease Surveil-
lance” 
A. Abstract 
International Classification of Diseases Ninth Revision-Clinical Modification (ICD-9-CM) codes 
have been proposed as a method of public health surveillance and are widely used in public health 
and clinical research.  However, ICD-9-CM codes have been found to have variable accuracy for both 
healthcare billing as well as for disease classification, and they have never been comprehensively 
validated for their use for surveillance.  Therefore, we undertook the most comprehensive analysis to 
date of the positive predictive values of ICD-9-CM codes for communicable diseases in 6 healthcare 
systems in North Carolina.  Stratified random samples of patient charts with ICD-9-CM diagnoses for 
communicable diseases were reviewed and evaluated for their concordance with the Centers for Dis-
ease Control and Prevention (CDC) surveillance case definitions.  Semi-Bayesian hierarchical re-
gression techniques were employed on our ensemble of disease-specific positive predictive values in 
order to reduce the overall mean squared error.  We found that for the majority for diseases with 
higher incidence and relatively straightforward laboratory-based diagnoses, the positive predictive 
values were high (>80%) with the important exception of tuberculosis which had a PPV of 23.6% 
(95% CI: 15.6, 46.5%).   
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B. Introduction 
International Classification of Diseases Ninth Revision-Clinical Modification codes (ICD-9-CM) 
codes, used on death certificates, in Medicaid records as well as for hospital and outpatient discharge 
diagnoses, have been proposed to be used as adjuncts to existing public health reporting systems 
[60].  In addition, ICD-9-CM codes are key data elements of the National Healthcare Survey, National 
Ambulatory Medical Care Survey, National Hospital Ambulatory Medical Care Survey, and the Na-
tional Hospital Discharge Survey which are commonly used for surveillance and research purposes 
[61].   The benefit of utilizing ICD-9-CM codes for surveillance and research are that they are stan-
dardized across healthcare systems, applied in both outpatient and inpatient settings, can be easily 
queried electronically, and are designed to represent a patient’s overall clinical diagnosis as the phy-
sician takes into account numerous clinical data (e.g., physical exam findings, laboratory findings, 
radiological findings).   
However, ICD-9-CM codes have been found to have variable accuracy for both healthcare billing 
[56] as well as for disease classification [57] due to both coding and physician errors.  In an overall 
assessment of the accuracy of ICD-9-CM codes for Medicare claims data, Fisher and colleagues 
found that diseases coded as infectious and parasitic diseases had 62.6-65.4% agreement with the 
abstracted hospital data [57].  In addition, the sensitivity of ICD-9-CM codes for five infectious dis-
eases (shigellosis, salmonellosis, giardiasis, hepatitis A and hepatitis B) studied at one medical cen-
ter was estimated to be only 53% (10/19) for inpatient cases and 7% (15/213) of outpatient cases 
[58].  Decreased sensitivity of ICD-9-CM codes in both inpatient and outpatient settings has been at-
tributed to laboratory results not available at the time the patient visit was coded and more complex 
clinical diagnoses were given priority over infectious disease clinical diagnosis codes.   
In addition to potentially low sensitivity of ICD-9-CM codes for communicable disease surveil-
lance, some disease codes may also have low positive predictive values.  One small validation study 
of ICD-9-CM codes for communicable disease surveillance found that 33% of outpatients and 35% of 
inpatients were incorrectly coded [27, 59].   An examination of the discordance between ICD-9-CM 
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diagnostic codes and active tuberculosis (TB) cases found several explanations for incorrect assign-
ment of codes – the patient was suspected to have active TB at discharge, but the disease was not 
yet confirmed; the patient had screening (i.e., tuberculin skin test placed) for evaluation of a latent 
tuberculosis infection; the patient had a history of treated tuberculosis; or the patient had an infection 
due to another species of Mycobacterium that was not included in the M.tuberculosis complex [15, 
17].   
Despite these recognized concerns over low sensitivity and low positive predictive value of ICD-
9-CM codes for communicable diseases, these codes have never been comprehensively validated for 
their use for surveillance though they continue to be utilized in both surveillance programs and re-
search studies.  Therefore, we have undertaken the most comprehensive validation study to date of 
the positive predictive values for ICD-9-CM codes for communicable disease surveillance. 
C. Materials and Methods 
A retrospective cohort study was conducted at 8 large North Carolina (NC) non-federal acute 
care healthcare systems that make up 32% of all inpatient visits and 23% of all outpatient visits in NC 
[65] and included both inpatients and outpatients who were assigned discharge diagnostic codes 
(ICD-9-CM) that correspond to communicable diseases that are reportable in NC (Appendix 1) during 
a ten-year study time period (1995-1997, 2000-2006).  Diseases were excluded if they were chronic 
infectious diseases thus resulting in a recurring assignment of ICD-9-CM code (e.g., HIV), if no spe-
cific ICD-9-CM code was available (e.g., viral hemorrhagic fever), or if the NC Department of Health 
and Human Services (NC DHHS) did not record patient identifiers in their surveillance database dur-
ing the entire study time period (e.g., gonorrhea).  Approval for the study was granted by the Institu-
tional Review Boards of all healthcare systems as well that of NC DHHS.   
Cases were matched from the healthcare system ICD-9-CM records to the NC DHHS surveil-
lance database using a unique identifier created by either social security number, or a combination of 
the first two letters of the last name, first letter of the first name, date of birth, and a 2 digit disease 
code.  Six of the healthcare systems participating in the overall retrospective cohort study completed 
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the positive predictive value study.  At each of these six healthcare systems, a stratified random sam-
ple of cases with ICD-9-CM codes in the year 2003 was selected for review to estimate the positive 
predictive value of ICD-9-CM codes for infectious diseases.  Charts were stratified by healthcare facil-
ity, by disease and by matching status (i.e., whether it was reported to the NC State Health Depart-
ment) and up to 5 charts were selected per strata, but at least 20% of charts were reviewed in each 
strata.    
Trained hospital-based public health epidemiologists (PHE) at each facility reviewed these 
charts for their concordance with published CDC case classification criteria for surveillance purposes 
[48].  Each selected patient chart was classified as either a true reportable case (i.e., confirmed, sus-
pect, or probable) or not a case based on specified laboratory, clinical and/or epidemiological case 
definition criteria.  Unadjusted disease-specific positive predictive values (PPV) were calculated 
based on the number of ICD-9-CM coded patients that were true cases by CDC criteria divided by the 
total number of ICD-9-CM coded patient charts that were reviewed.  For each strata, empirical conti-
nuity corrections were used when no true cases were found upon review [75] and disease-specific 
data were aggregated across matching strata and healthcare facilities with sample proportion weight-
ing.  Adjusted completeness proportions and 95% uncertainty intervals (UI) were calculated using 
semi-Bayesian hierarchical regression analysis [77] as recommended to reduce the mean squared 
error when an ensemble of measures are estimated [71].   
This semi-Bayesian hierarchical regression analysis utilizes prior covariates data that help to ex-
plain the mean of the ensemble of estimates as well as a specified prior variance (tau2) of the distribu-
tion.  Traditional maximum likelihood estimates (i.e., unadjusted estimates as presented here) can be 
viewed as a special case of semi-Bayesian analysis in which the prior variance is infinite.  By specify-
ing even a moderately informative prior variance such as a tau2 indicating that 95% of all complete-
ness proportions lie between 0.4% and 90%, an appreciable reduction in the overall mean squared 
error can be expected with a shift in the point estimate and a narrowing of the 95% uncertainty inter-
val for each PPV, with the relative degree of narrowing being greater for disease with less informa-
tion. 
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A sensitivity analysis was conducted on the specified prior variance (tau2) using high, medium 
and low tau2 values that assumed that 95% of the PPV were within the following ranges: [0.4, 99%], 
[0.4, 90%], [16, 70%], respectively.  Sensitivity analyses were also conducted on the inclusion or ex-
clusion of prior covariates: whether or not the disease had a reportable laboratory result, whether or 
not the disease had reportable serology test results, and whether or not the disease is rare in NC 
(<10 reported cases statewide annually).  
D. Results 
A total of 670 charts were reviewed for 47 different diseases.  Unadjusted and semi-Bayesian 
adjusted disease-specific PPVs with 95% confidence intervals (CI) and uncertainty intervals (UI), re-
spectively are summarized in Table 13.  Semi-Bayesian adjusted PPVs ranged from 20.3% to 96%.  
Many of the higher incident diseases in NC (e.g., pertussis, invasive group A streptococcal infection, 
campylobacteriosis, shigellosis, salmonellosis) and more severe (e.g., meningococcal meningitis, 
hemolytic uremic syndrome) had PPVs exceeding 80%, although tuberculosis was very low with a 
PPV and 95% UI of 28.60% (15.57-46.53%).  Marked differences in the unadjusted to adjusted point 
estimates were noted for Rocky Mountain spotted fever (RMSF), Lyme disease, Hemophilus influen-
zae invasive disease, and acute hepatitis A; however, wide uncertainty intervals also reflect the im-
precision in these estimates. 
The sensitivity analysis of the tau2 values showed that the point estimates and UI were relatively 
insensitive to dramatic changes in tau2; for example, for tuberculosis with a low tau, the PPV and 95% 
UI was estimated as: 34% (20-51%), with a medium tau, 27% (15-45%); and with a high tau, 25% 
(13-42%).  However, the sensitivity analyses examining the use of prior covariates (Table 14) were 
shown to have dramatic effects on the point estimates for diseases with sparse data (e.g., Vibrio in-
fection, cholera, measles) and only produced minor changes for diseases with more data (e.g., sal-
monellosis, meningococcal meningitis). 
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Table 13.  ICD-9-CM Positive Predictive Values (PPV) for CDC Communicable Disease Surveillance Case Definitions 
Communicable Disease 
Number 
Charts Re-
viewed 
Unadjusted 
PPV 
Lower 
95% CI 
Upper 
95% CI 
Semi-Bayesian 
Adjusted PPV 
Lower 
95% UI 
Upper 
95% UI 
Arboviral Encephalitis 6 99.65% 0.01% 100.00% 90.33% 4.02% 99.95% 
Brucellosis 3 0.16% 0.00% 100.00% 22.73% 0.08% 99.10% 
Campylobacteriosis 16 99.34% 2.65% 100.00% 90.37% 33.00% 99.44% 
Cholera 1 0.23% 0.00% 100.00% 23.06% 0.08% 99.13% 
Creutzfeldt-Jakob Disease 5 0.08% 0.00% 100.00% 49.18% 6.74% 92.84% 
Cryptosporidiosis 13 99.61% 0.01% 100.00% 88.99% 27.52% 99.42% 
Cyclosporiasis 1 0.23% 0.00% 100.00% 23.06% 0.08% 99.13% 
Dengue 2 0.23% 0.00% 100.00% 25.38% 0.72% 94.13% 
Diphtheria 2 0.12% 0.00% 100.00% 52.97% 0.39% 99.69% 
E. coli O157:H7 1 99.77% 0.00% 100.00% 88.11% 24.84% 99.40% 
Foodborne Disease, Staphy-
lococcal 1 99.77% 0.00% 100.00% 96.02% 6.45% 99.99% 
Granulocytic Ehrlichiosis 3 0.06% 0.00% 97.60% 20.29% 0.61% 91.31% 
Hantavirus 1 0.23% 0.00% 100.00% 25.77% 0.72% 94.31% 
Hemolytic Uremic Syndrome 24 92.57% 67.30% 98.69% 84.62% 55.60% 96.03% 
Hepatitis A, acute 62 7.79% 0.00% 99.99% 85.37% 22.23% 99.17% 
Hemophilus influenzae, inva-
sive disease 59 6.50% 0.00% 100.00% 86.67% 23.22% 99.29% 
Legionellosis 14 99.43% 0.35% 100.00% 89.65% 30.01% 99.43% 
Leptospirosis 5 0.16% 0.00% 100.00% 22.73% 0.08% 99.10% 
Listeriosis 15 99.75% 0.12% 100.00% 89.54% 29.14% 99.44% 
Lyme Disease 46 5.62% 0.00% 100.00% 87.10% 23.58% 99.33% 
Malaria 14 99.23% 0.00% 100.00% 88.44% 25.93% 99.40% 
Measles 3 99.31% 0.00% 100.00% 28.32% 0.86% 94.76% 
Meningococcal meningitis 31 98.19% 56.67% 99.96% 93.36% 55.41% 99.38% 
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Communicable Disease 
Number 
Charts Re-
viewed 
Unadjusted 
PPV 
Lower 
95% CI 
Upper 
95% CI 
Semi-Bayesian 
Adjusted PPV 
Lower 
95% UI 
Upper 
95% UI 
Monocytic Ehrlichosis 1 99.77% 0.00% 100.00% 89.56% 3.29% 99.95% 
Mumps 9 99.54% 0.00% 100.00% 28.27% 0.85% 94.77% 
Plague 3 0.14% 0.00% 100.00% 22.87% 0.08% 99.12% 
Pneumococcal meningitis 26 99.40% 46.16% 100.00% 93.08% 47.18% 99.51% 
Poliovirus 2 0.23% 0.00% 100.00% 22.71% 0.08% 99.09% 
Psittacosis 4 0.23% 0.00% 100.00% 25.38% 0.72% 94.13% 
Q fever 4 50.00% 12.35% 87.65% 40.71% 9.48% 81.82% 
Rabies, human 1 0.23% 0.00% 100.00% 23.06% 0.08% 99.13% 
Rocky Mountain spotted fe-
ver 
46 21.13% 0.06% 99.20% 83.32% 3.96% 99.84% 
Rubella Congenital Syn-
drome 2 0.23% 0.00% 100.00% 25.77% 0.72% 94.31% 
Rubella 7 0.10% 0.00% 100.00% 24.99% 0.71% 93.97% 
Salmonellosis 64 99.52% 83.48% 99.99% 95.64% 66.04% 99.60% 
Shigellosis 37 99.62% 17.67% 100.00% 91.75% 38.55% 99.50% 
Smallpox 3 0.12% 0.00% 100.00% 21.84% 0.08% 99.01% 
Streptococcal Infection, 
group A, invasive 12 99.44% 0.00% 100.00% 88.79% 26.98% 99.41% 
Tetanus 3 0.23% 0.00% 100.00% 49.38% 6.79% 92.89% 
Toxic Shock Syndrome 25 43.32% 13.56% 78.82% 45.11% 17.53% 76.06% 
Trichinosis 4 0.16% 0.00% 100.00% 23.03% 0.08% 99.13% 
Tuberculosis 73 23.39% 12.10% 40.37% 28.60% 15.57% 46.53% 
Tularemia 2 0.23% 0.00% 100.00% 23.06% 0.08% 99.13% 
Typhoid, acute 1 99.77% 0.00% 100.00% 50.62% 7.11% 93.21% 
Vaccinia 3 0.23% 0.00% 100.00% 22.71% 0.08% 99.09% 
Vibrio infection, other 1 99.77% 0.00% 100.00% 23.95% 0.08% 99.17% 
Whooping Cough (Pertussis) 9 99.63% 0.00% 100.00% 90.09% 3.78% 99.95% 
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Table 14.  Sensitivity Analysis for Prior Covariates on Disease-Specific Positive Predictive Values (95% UI) 
Communicable Disease All Prior Covariates No Prior Covariates Lab Covariate Alone 
Serology Covariate 
Alone 
Rare Disease 
Covariate Alone 
Arboviral Encephalitis 0.9 (0.04, 1) 0.78 (0.18, 0.98) 0.79 (0.17, 0.99) 0.45 (0.02, 0.97) 0.89 (0.28, 0.99) 
Brucellosis 0.23 (0, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Campylobacteriosis 0.9 (0.33, 0.99) 0.82 (0.22, 0.99) 0.82 (0.22, 0.99) 0.6 (0.11, 0.95) 0.9 (0.34, 0.99) 
Cholera 0.23 (0, 0.99) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Creutzfeldt-Jakob Disease 0.49 (0.07, 0.93) 0.75 (0.15, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Cryptosporidiosis 0.89 (0.28, 0.99) 0.78 (0.18, 0.98) 0.79 (0.17, 0.99) 0.54 (0.08, 0.94) 0.89 (0.28, 0.99) 
Cyclosporiasis 0.23 (0, 0.99) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Dengue 0.25 (0.01, 0.94) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.4 (0.02, 0.96) 0.49 (0.07, 0.93) 
Diptheria 0.53 (0, 1) 0.76 (0.15, 0.98) 0.49 (0.07, 0.93) 0.4 (0.02, 0.96) 0.49 (0.07, 0.93) 
E.coli O157:H7 0.88 (0.25, 0.99) 0.77 (0.16, 0.98) 0.78 (0.15, 0.99) 0.51 (0.07, 0.93) 0.88 (0.26, 0.99) 
Foodborne Disease, Staphylo-
coccal 0.96 (0.06, 1) 0.77 (0.16, 0.98) 0.51 (0.07, 0.93) 0.51 (0.07, 0.93) 0.88 (0.26, 0.99) 
Granulocytic Ehrlichiosis 0.2 (0.01, 0.91) 0.67 (0.11, 0.97) 0.68 (0.11, 0.97) 0.33 (0.01, 0.94) 0.4 (0.05, 0.9) 
Hantavirus 0.26 (0.01, 0.94) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.41 (0.02, 0.96) 0.49 (0.07, 0.93) 
Hemophilus influenzae, inva-
sive disease 0.87 (0.23, 0.99) 0.74 (0.15, 0.98) 0.75 (0.14, 0.98) 0.48 (0.07, 0.92) 0.87 (0.24, 0.99) 
Hemolytic Uremic Syndrome 0.85 (0.56, 0.96) 0.89 (0.63, 0.97) 0.85 (0.56, 0.96) 0.85 (0.56, 0.96) 0.85 (0.56, 0.96) 
Hepatitis A, acute 0.85 (0.22, 0.99) 0.73 (0.14, 0.98) 0.74 (0.14, 0.98) 0.47 (0.07, 0.92) 0.86 (0.23, 0.99) 
Legionellosis 0.9 (0.3, 0.99) 0.8 (0.2, 0.98) 0.81 (0.19, 0.99) 0.57 (0.1, 0.94) 0.9 (0.31, 0.99) 
Leptospirosis 0.23 (0, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Listeriosis 0.9 (0.29, 0.99) 0.8 (0.19, 0.98) 0.8 (0.18, 0.99) 0.56 (0.09, 0.94) 0.9 (0.3, 0.99) 
Lyme Disease 0.87 (0.24, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.87 (0.24, 0.99) 
Malaria 0.88 (0.26, 0.99) 0.77 (0.17, 0.98) 0.78 (0.16, 0.99) 0.52 (0.08, 0.93) 0.89 (0.27, 0.99) 
Measles 0.28 (0.01, 0.95) 0.77 (0.17, 0.98) 0.78 (0.16, 0.99) 0.43 (0.02, 0.97) 0.52 (0.08, 0.94) 
Meningococcal meningitis 0.93 (0.55, 0.99) 0.89 (0.45, 0.99) 0.89 (0.45, 0.99) 0.79 (0.3, 0.97) 0.93 (0.56, 0.99) 
Monocytic Ehrlichosis 0.9 (0.03, 1) 0.77 (0.16, 0.98) 0.78 (0.15, 0.99) 0.42 (0.02, 0.97) 0.88 (0.26, 0.99) 
Mumps 0.28 (0.01, 0.95) 0.77 (0.17, 0.98) 0.78 (0.16, 0.99) 0.43 (0.02, 0.97) 0.52 (0.08, 0.94) 
Plague 0.23 (0, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Pneumococcal meningitis 0.93 (0.47, 1) 0.87 (0.36, 0.99) 0.88 (0.35, 0.99) 0.73 (0.21, 0.97) 0.93 (0.48, 1) 
Poliovirus 0.23 (0, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Psittacosis 0.25 (0.01, 0.94) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.4 (0.02, 0.96) 0.49 (0.07, 0.93) 
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Communicable Disease All Prior Covariates No Prior Covariates Lab Covariate Alone 
Serology Covariate 
Alone 
Rare Disease 
Covariate Alone 
Q fever 0.41 (0.09, 0.82) 0.6 (0.23, 0.89) 0.61 (0.23, 0.89) 0.47 (0.12, 0.85) 0.5 (0.17, 0.83) 
Rabies, human 0.23 (0, 0.99) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Rocky Mountain spotted fever 0.83 (0.04, 1) 0.69 (0.14, 0.97) 0.7 (0.14, 0.97) 0.38 (0.02, 0.94) 0.82 (0.22, 0.99) 
Rubella Congenital Syndrome 0.26 (0.01, 0.94) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.41 (0.02, 0.96) 0.49 (0.07, 0.93) 
Rubella 0.25 (0.01, 0.94) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.39 (0.02, 0.96) 0.48 (0.07, 0.93) 
Salmonellosis 0.96 (0.66, 1) 0.93 (0.56, 0.99) 0.93 (0.56, 0.99) 0.85 (0.41, 0.98) 0.96 (0.67, 1) 
Shigellosis 0.92 (0.39, 0.99) 0.84 (0.27, 0.99) 0.85 (0.27, 0.99) 0.66 (0.14, 0.96) 0.92 (0.39, 0.99) 
Smallpox 0.22 (0, 0.99) 0.74 (0.14, 0.98) 0.75 (0.14, 0.98) 0.47 (0.06, 0.92) 0.47 (0.06, 0.92) 
Streptococcal Infection, group 
A, invasive 0.89 (0.27, 0.99) 0.78 (0.17, 0.98) 0.79 (0.17, 0.99) 0.53 (0.08, 0.94) 0.89 (0.28, 0.99) 
Tetanus 0.49 (0.07, 0.93) 0.76 (0.15, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Toxic Shock Syndrome 0.45 (0.18, 0.76) 0.53 (0.22, 0.82) 0.45 (0.18, 0.76) 0.45 (0.18, 0.76) 0.45 (0.18, 0.76) 
Trichinosis 0.23 (0, 0.99) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Tuberculosis 0.29 (0.16, 0.47) 0.27 (0.15, 0.45) 0.27 (0.15, 0.45) 0.25 (0.14, 0.42) 0.29 (0.16, 0.47) 
Tularemia 0.23 (0, 0.99) 0.76 (0.15, 0.98) 0.77 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Typhoid, acute 0.51 (0.07, 0.93) 0.77 (0.16, 0.98) 0.51 (0.07, 0.93) 0.51 (0.07, 0.93) 0.51 (0.07, 0.93) 
Vaccinia 0.23 (0, 0.99) 0.75 (0.15, 0.98) 0.76 (0.14, 0.98) 0.49 (0.07, 0.93) 0.49 (0.07, 0.93) 
Vibrio infection, other 0.24 (0, 0.99) 0.77 (0.16, 0.98) 0.78 (0.15, 0.99) 0.51 (0.07, 0.93) 0.51 (0.07, 0.93) 
Whooping Cough (Pertussis) 0.9 (0.04, 1) 0.78 (0.17, 0.98) 0.79 (0.17, 0.99) 0.44 (0.02, 0.97) 0.89 (0.28, 0.99) 
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E. Discussion 
We found that for many diseases of particular interest to the public health community the positive 
predictive values of the ICD-9-CM codes were relatively high with a notable exception of tuberculosis.   
Tuberculosis posed a particular problem with assignment of ICD-9-CM codes because of the difficul-
ties with clinical diagnoses, that is, Mycobacteria are slow-growing organisms, patients can be latently 
infected without having active disease, and patients are often started on empiric therapy until active 
tuberculosis can be ruled out because of the public health impact of a communicable airborne dis-
ease.  Other diseases with low positive predictive values estimates included unlikely or improbable 
diseases such as human rabies, hantavirus, poliovirus, smallpox, plague; diseases which are rela-
tively rare, such as measles, mumps, rubella, Creutzfeldt-Jakob disease, and diseases which have 
complex surveillance case definitions, such as toxic shock syndrome.  Hemolytic uremic syndrome 
also has a complex surveillance case definition, but is almost always associated with isolation of E. 
coli O157:H7, which may explain its higher PPV than toxic shock syndrome.    
We believe that the semi-Bayesian adjusted estimates offer improved overall accuracy and pre-
cision for our ensemble of PPV estimates.  Based on the results of our sensitivity analysis for the prior 
covariates, we elected to use the model that included all prior covariates as it allowed for more con-
servative estimates with a wider range of values.  In addition, we chose a prior variance (tau2) that 
conservatively reduced the overall mean’s likely 95% confidence interval from 0-100% to 0.4-90%.  
The effect of semi-Bayesian analysis methods can be seen in the change in PPVs for RMSF, Lyme 
disease, H. influenzae invasive disease, and acute hepatitis A.  All of these diseases had relatively 
low positive predictive values (<25%) that after semi-Bayesian adjustment increased to over 80%, as 
they became shrunk towards the mean of their prior covariates (i.e., they are all not rare diseases and 
have laboratory results).  However, the imprecision of these estimates is still reflected in their wide 
uncertainty intervals.  Furthermore, these diseases share similar properties with other low PPV dis-
eases in that their case definitions are complex and/or clinical diagnoses are difficult to make.  Both 
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RMSF and Lyme disease require acute and convalescent serology for confirmation of disease to 
meet the confirmed case definition.  Invasive disease, including pneumonia, with H. influenzae re-
quires isolation of the bacteria from a sterile body site and positive hepatitis A serology results indicat-
ing vaccination or a previous infection can be misinterpreted as an acute infection.   
Despite the use of trained medical coders at healthcare systems who review providers’ docu-
mentation to assign the ICD-9-CM diagnosis codes following the patient’s discharge or outpatient 
visit, these codes are not assigned without errors.  Occasionally, we found ICD-9-CM codes that were 
mistakenly assigned for a similar sounding disease; for example, a patient with a head ultrasound 
abbreviated as HUS, was coded as hemolytic uremic syndrome or a patient with pleural plaques 
noted on a chest radiograph was assigned a diagnosis code for plague.  Sometimes similar infectious 
diseases were mistakenly assigned; for example, hepatitis C instead of hepatitis A or monocytic ehr-
lichiosis instead of granulocytic ehrlichiosis.  Finally, there were a limited number of cases with no 
data in the medical record to support the diagnostic code.  However, these situations occurred most 
often with rare or difficult to diagnose diseases. 
This study may have been limited by the availability of data on which to evaluate each case’s 
concordance with CDC case definitions.  While the CDC case definitions are standardized and util-
ized nationwide for communicable disease surveillance, some of the case definitions include complex 
criteria that are difficult to apply objectively to clinical cases.  Each PHE was trained to apply these 
case definitions as objectively as possible during the chart review in the validation study, but misclas-
sification of patients could have occurred due to incomplete clinical data in the patient’s medical re-
cord or the interpretation of a complex case definition criteria.  However, a senior medical epidemi-
ologist at the NC DHHS was available to provide assistance with interpretation of complex case defi-
nition criteria and application to clinical or laboratory data.   
In order to truly understand the utility of ICD-9-CM codes for infectious disease surveillance, ad-
ditional comprehensive studies are warranted to estimate the sensitivity of ICD-9-CM codes.  While 
this study has provided the most comprehensive assessment of positive predictive values for ICD-9-
CM for infectious disease surveillance to date, we were not able to estimate the sensitivity of ICD-9-
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CM codes due to the cost and difficulties in identifying an appropriate gold standard.  A previous 
study conducted by Watkins et al. which showed low ICD-9-CM sensitivity used laboratory records as 
the “gold” standard for five laboratory reportable diseases; however, this method is only appropriate 
for those diseases with straightforward laboratory findings.  Ideally, a complete medical record review 
would serve as a gold standard, but would be both extremely costly and time-consuming and would 
be very inefficient for most of the infectious diseases with relatively low incidence rates in the general 
population.  With estimates of both positive predictive values and sensitivity of ICD-9-CM codes, not 
only can the utility of these codes be completely described but an adjustment of ICD-9-CM based 
studies can be conducted using Bayes Theorem (Appendix 3).  
The standardized designation of ICD-9-CM codes to capture a patient’s clinical diagnosis make 
them attractive data elements for automated, electronic disease surveillance and as new case defini-
tions are developed to be compatible with automated, electronic public health surveillance, the utility 
of ICD-9-CM codes should be carefully considered.  Based on our findings, we believe that ICD-9-CM 
codes for communicable diseases have high enough positive predictive values to be useful for dis-
eases which are relatively common and have simple case definitions and clinical diagnoses.  ICD-9-
CM codes are inefficient for studying rare diseases (e.g., brucellosis, Q fever) or to conduct surveil-
lance for unlikely diseases (e.g., smallpox, anthrax) because of the high number of false positive 
cases.   
 
 
 VI. Chapter 6: Conclusions 
A. Recapitulation of Specific Aims 
 
Aim 1:  Determine the positive predictive value (PPV) of diagnostic codes for communicable disease 
case ascertainment and surveillance.  That is, given that a patient is assigned a diagnostic code for a 
communicable disease, the probability that the patient meets the communicable disease case defini-
tion will be determined. 
 
Conclusions:  We found that for many diseases of particular interest to the public health community 
the positive predictive values of the ICD-9-CM codes were relatively high with the notable exception 
of tuberculosis.   Other diseases with low positive predictive values estimates included unlikely or im-
probable diseases such as human rabies, hantavirus, poliovirus, smallpox, plague; diseases which 
are relatively rare, such as measles, mumps, rubella, Creutzfeldt-Jakob disease, and diseases which 
have complex surveillance case definitions, such as toxic shock syndrome.   
 
Aim 2:  Describe the disease-specific completeness of state-required communicable disease report-
ing, overall state-required communicable disease reporting over a 10 year time period, and overall 
state-required communicable disease reporting for different healthcare systems. 
 
Conclusions:  Disease-specific reporting completeness proportions were estimated to be very low and 
varied greatly based on disease.  One clear pattern that emerged in our findings was that diseases 
with fewer clinical criteria and laboratory-based case definitions tended to have higher reporting rates.  
The overall disease reporting completeness proportions for eight different healthcare systems ranged 
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widely from 2-30% and the general trend of the yearly reporting completeness proportions suggests 
that disease reporting has improved over time yet remains very low.   
 
Aim 3:  Utilize hierarchical Bayesian analysis techniques to provide more precise estimates of dis-
ease-specific reporting completeness and positive predictive values of ICD-9-CM codes.    
 
Conclusions:  We believe that the semi-Bayesian adjusted estimates offer improved overall accuracy 
and precision for our ensemble of disease reporting completeness proportions and PPV estimates.  
We did note several dramatic shifts in the reporting completeness proportions and PPVs after semi-
Bayesian adjustments.  These shifts reflected both the imprecision in each disease’s measured esti-
mates and the shrinkage of their proportions to others in the same prior covariate group.   This finding 
reinforces the importance of careful specification of prior covariates as well as judicious examination 
and interpretation of unadjusted and semi-Bayesian adjusted estimates along with their precision.   
B. Recommendations 
In order to fully understand the utility of ICD-9-CM codes for infectious disease surveillance, ad-
ditional comprehensive studies are warranted to estimate the sensitivity of ICD-9-CM codes.  While 
this study has provided the most comprehensive assessment of positive predictive values for ICD-9-
CM for infectious disease surveillance to date, we were not able to estimate the sensitivity of ICD-9-
CM codes due to the cost and difficulties in identifying an appropriate gold standard.  When estimates 
of both positive predictive values and sensitivity of ICD-9-CM codes are available, not only can the 
utility of these codes be completely described but an adjustment of ICD-9-CM based studies can be 
conducted using Bayes Theorem. 
However, based on our findings, we believe that ICD-9-CM codes for communicable diseases 
have high enough positive predictive values to be useful for studying diseases which are relatively 
common and have simple case definitions and clinical diagnoses.  ICD-9-CM codes are inefficient for 
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studying rare diseases (e.g., brucellosis, Q fever) or to conduct surveillance for unlikely diseases 
(e.g., smallpox, anthrax) because of the high number of false positive cases.   
We found disease reporting to be very low overall even for diseases that require immediate pub-
lic health intervention.  Complete communicable disease reporting is critical to the success of the 
public health surveillance system, and physicians and laboratories should be provided with ongoing 
education on the importance of public health surveillance.  The benefit of programs like hospital-
based PHEs is that they can be directly involved in developing and delivering this education to physi-
cians and laboratorians in their healthcare systems in grand round formats, inservices, and direct in-
teractions. 
One clear pattern that emerged in our findings was that diseases with fewer clinical criteria and 
laboratory-based case definitions tended to have higher reporting rates.  We also found that the re-
quirement for laboratories to report diseases with positive laboratory findings improved overall dis-
ease reporting though it still remained low.  Therefore, the impact of the complexity of case definitions 
on the reporting completeness should be a consideration in surveillance system development and 
maintenance.   
Future studies may include an investigation on predictors of reporting or timeliness of reporting 
related to the patient interaction (e.g., number of visits, length of stay, and location of visit) and dis-
ease characteristics (e.g., mode of transmission, whether the disease has laboratory test results).  
Additional studies are also warranted to investigate what healthcare system factors predict higher 
reporting rates among the healthcare systems as we did not find that assigning responsibility to an-
other entity (i.e., PHE, infection preventionist) had a statistically significant effect on reporting.  Re-
sults from these additional studies may help in the improvement of current surveillance strategies or 
the development of surveillance innovations.   
Finally, both state health departments and healthcare systems should consider investing in tech-
nology for automating both disease reporting and surveillance data collection.  Automated disease 
reporting could be achieved by standardized queries directly from the electronic health records for 
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key laboratory results and for simplified or proxy clinical case definitions using ICD-9-CM diagnosis 
codes or free-text admission diagnoses.  Upon recognition of these potential case-patients, automat-
ing surveillance data collection directly from electronic health records to populate data fields for basic 
patient demographics and laboratory results could also significantly reduce administrative time for 
physicians and health department officials and expedite disease investigations.  Using the electronic 
health record for automated case-finding and data collection would transition our current public health 
surveillance system from passive to active and thereby overcome the major barriers to complete, ac-
curate and timely communicable disease reporting and surveillance. 
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VII. Appendices
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Appendix 1:  ICD-9-CM code list 
 
Anthrax 022 ANTHRAX 
Anthrax 022.0 CUTANEOUS ANTHRAX 
Anthrax 022.1 PULM ANTHRAX 
Anthrax 022.2 GASTROINTESTINAL ANTHRAX 
Anthrax 022.3 ANTHRAX SEPTICEMIA 
Anthrax 022.8 OTH SPEC MANIFESTATIONS OF ANTHRAX 
Anthrax 022.9 ANTHRAX, UNSPEC 
Anthrax 484.5 PNEUMONIA IN ANTHRAX 
Botulism 005.1 BOTULISM 
Brucellosis 023 BRUCELLOSIS 
Brucellosis 023.0 BRUCELLA MELITENSIS 
Brucellosis 023.1 BRUCELLA ABORTUS 
Brucellosis 023.2 BRUCELLA SUIS 
Brucellosis 023.3 BRUCELLA CANIS 
Brucellosis 023.8 OTH BRUCELLOSIS 
Brucellosis 023.9 BRUCELLOSIS, UNSPEC 
Campylobacter 008.43 INTESTINAL INFEC DUE TO CAMPYLOBACTER 
Chancroid 099.0 CHANCROID 
Cholera 001.0 CHOLERA DUE TO VIBRIO CHOLERAE 
Cholera 001.1 CHOLERA DUE TO VIBRIO CHOLERAE EL TOR 
Cryptosporidiosis 007.4 CRYPTOSPORIDIOSIS 
Cyclosporiasis 007.5 CYCLOSPORIASIS 
Dengue 061 DENGUE 
Dengue 065.4 HEMMORRHAGIC FEVER CAUSED BY DENGUE VIRUS 
Diphtheria 032.0 FAUCIAL DIPHTHERIA 
Diphtheria 032.1 NASOPHARYNGEAL DIPHTHERIA 
Diphtheria 032.2 ANTERIOR NASAL DIPHTHERIA 
Diphtheria 032.3 LARYNGEAL DIPHTHERIA 
E.coli 017:H7 008.04 INTESTINAL INFEC DUE TO ENTEROHEMORRHAGIC E. COLI 
Ehrlichiosis, granulocytic 082.40 EHRLICHIOSIS 
Ehrlichiosis, granulocytic 082.49 OTH EHRLICHIOSIS 
Ehrlichiosis, monocytic 082.41 EHRLICHIOSIS CHAFEENSIS (E CHAFEENSIS) 
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Encephalitis, Arboviral, CAL 062.5 CALIFORNIA VIRUS ENCEPHALITIS 
Encephalitis, Arboviral, EEE 062.2 EASTERN EQUINE ENCEPHALITIS 
Encephalitis, Arboviral, WNV 066.4 WEST NILE FEVER 
Encephalitis, Arboviral, WNV 066.40 WEST NILE FEVER, UNSPECIFIED 
Encephalitis, Arboviral, WNV 066.41 WEST NILE FEVER WITH ENCEPHALITIS 
Encephalitis, Arboviral, WNV 066.42 WEST NILE FEVER WITH OTHER NEUROLOGIC MANIFESTATION 
Encephalitis, Arboviral, WNV 066.49 WEST NILE FEVER WITH OTHER COMPLICATIONS 
Foodborne Disease: C. perfringens 005.2 FOOD POISONING DUE TO CLOSTRIDIUM PERFRINGENS (C. WELCHII) 
Foodborne Disease: Staphylococcal 005.0 STAPHYLOCOCCAL FOOD POISONING 
Hantavirus 079.81 HANTAVIRUS 
Hemolytic Uremic Syndrome 283.11 HEMOLYTIC-UREMIC SYNDROME 
Hemophilus Influenzae, Invasive Dis-
ease 038.41 SEPTICEMIA DUE TO HEMOPHILUS INFLUENZAE (H. INFLUENZAE) 
Hemophilus Influenzae, Invasive Dis-
ease 320.0 HEMOPHILUS MENINGITIS 
Hemophilus Influenzae, Invasive Dis-
ease 482.2 PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE (H. INFLUENZAE) 
Hepatitis A 070 VIRAL HEP A WITH HEPATIC COMA 
Hepatitis A 070.1 VIRAL HEP A NO HEPATIC COMA 
Legionellosis 482.84 PNEUMONIA DUE TO LEGIONNAIRES' DISEASE 
Leptospirosis 100 LEPTOSPIROSIS 
Leptospirosis 100.0 LEPTOSPIROSIS ICTEROHEMORRHAGICA 
Leptospirosis 100.8 OTH SPEC LEPTOSPIRAL INFEC 
Leptospirosis 100.81 LEPTOSPIRAL MENINGITIS (ASEPTIC) 
Leptospirosis 100.89 OTH SPEC LEPTOSPIRAL INFEC 
Leptospirosis 100.9 LEPTOSPIROSIS, UNSPEC 
Listeriosis 027.0 LISTERIOSIS 
Lyme Disease 088.81 LYME DISEASE 
Malaria 084 MALARIA 
Malaria 084.0 FALCIPARUM MALARIA (MALIGNANT TERTIAN) 
Malaria 084.1 VIVAX MALARIA (BENIGN TERTIAN) 
Malaria 084.2 QUARTAN MALARIA 
Malaria 084.3 OVALE MALARIA 
Malaria 084.4 OTH MALARIA 
Malaria 084.5 MIXED MALARIA 
Malaria 084.6 MALARIA, UNSPEC 
  
 
85
 
Malaria 084.7 INDUCED MALARIA 
Malaria 084.8 BLACKWATER FEVER 
Malaria 084.9 OTH PERNICIOUS COMPLICATIONS OF MALARIA 
Measles (rubeola) 055 MEASLES 
Measles (rubeola) 055.0 POSTMEASLES ENCEPHALITIS 
Measles (rubeola) 055.1 POSTMEASLES PNEUMONIA 
Measles (rubeola) 055.2 POSTMEASLES OTITIS MEDIA 
Measles (rubeola) 055.7 MEASLES WITH OTH SPEC COMPLICATIONS 
Measles (rubeola) 055.71 MEASLES KERATOCONJUNCTIVITIS 
Measles (rubeola) 055.79 MEASLES WITH OTH SPEC COMPLICATIONS 
Measles (rubeola) 055.8 MEASLES WITH UNSPEC COMPLICATION 
Measles (rubeola) 055.9 MEASLES NO COMPLICATION 
Meningitis, Pneumococcal meningitis 320.1 PNEUMOCOCCAL MENINGITIS 
Meningococcal Disease 036 MENINGOCOCCAL INFEC 
Meningococcal Disease 036.0 MENINGOCOCCAL MENINGITIS 
Meningococcal Disease 036.1 MENINGOCOCCAL ENCEPHALITIS 
Meningococcal Disease 036.2 MENINGOCOCCEMIA 
Meningococcal Disease 036.3 WATERHOUSE-FRIDERICHSEN SYNDROME, MENINGOCOCCAL 
Meningococcal Disease 036.4 MENINGOCOCCAL CARDITIS 
Meningococcal Disease 036.40 MENINGOCOCCAL CARDITIS, UNSPEC 
Meningococcal Disease 036.41 MENINGOCOCCAL PERICARDITIS 
Meningococcal Disease 036.42 MENINGOCOCCAL ENDOCARDITIS 
Meningococcal Disease 036.43 MENINGOCOCCAL MYOCARDITIS 
Meningococcal Disease 036.8 OTH SPEC MENINGOCOCCAL INFEC 
Meningococcal Disease 036.81 MENINGOCOCCAL OPTIC NEURITIS 
Meningococcal Disease 036.82 MENINGOCOCCAL ARTHROPATHY 
Meningococcal Disease 036.89 OTH SPEC MENINGOCOCCAL INFEC 
Mumps 072 MUMPS 
Mumps 072.0 MUMPS ORCHITIS 
Mumps 072.1 MUMPS MENINGITIS 
Mumps 072.2 MUMPS ENCEPHALITIS 
Mumps 072.3 MUMPS PANCREATITIS 
Mumps 072.7 MUMPS WITH OTH SPEC COMPLICATIONS 
Mumps 072.71 MUMPS HEPATITIS 
Mumps 072.72 MUMPS POLYNEUROPATHY 
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Mumps 072.79 MUMPS WITH OTH SPEC COMPLICATIONS 
Mumps 072.8 MUMPS WITH UNSPEC COMPLICATION 
Mumps 072.9 MUMPS NO COMPLICATION 
Pelvic Inflammatory Disease 614.9 UNSPECIFIED INFLAMMATORY DISEASE OF FEMALE PELVIC ORGANS AND TISSUES 
Plague 020 PLAGUE 
Plague 020.0 BUBONIC PLAGUE 
Plague 020.1 CELLULOCUTANEOUS PLAGUE 
Plague 020.2 SEPTICEMIC PLAGUE 
Plague 020.3 PRIM PNEUMONIC PLAGUE 
Plague 020.4 SECONDARY PNEUMONIC PLAGUE 
Plague 020.5 PNEUMONIC PLAGUE, UNSPEC 
Plague 020.8 OTH SPEC TYPES OF PLAGUE 
Plague 020.9 PLAGUE, UNSPEC 
Poliomyelitis, Paralytic 045 ACUTE POLIOMYELITIS 
Poliomyelitis, Paralytic 045.0 ACUTE PARALYTIC POLIOMYELITIS SPEC AS BULBAR 
Poliomyelitis, Paralytic 045.00 ACUTE PARALYTIC POLIOMYELITIS SPEC AS BULBAR, UNSPEC OF POLIOVIRUS 
Poliomyelitis, Paralytic 045.01 ACUTE PARALYTIC POLIOMYELITIS SPEC AS BULBAR, POLIOVIRUS TYPE I 
Poliomyelitis, Paralytic 045.02 ACUTE PARALYTIC POLIOMYELITIS SPEC AS BULBAR, POLIOVIRUS TYPE II 
Poliomyelitis, Paralytic 045.03 ACUTE PARALYTIC POLIOMYELITIS SPEC AS BULBAR, POLIOVIRUS TYPE III 
Poliomyelitis, Paralytic 045.1 ACUTE POLIOMYELITIS WITH OTH PARALYSIS 
Poliomyelitis, Paralytic 045.10 ACUTE POLIOMYELITIS WITH OTH PARALYSIS, UNSPEC OF POLIOVIRUS 
Poliomyelitis, Paralytic 045.11 ACUTE POLIOMYELITIS WITH OTH PARALYSIS, POLIOVIRUS TYPE I 
Poliomyelitis, Paralytic 045.12 ACUTE POLIOMYELITIS WITH OTH PARALYSIS, POLIOVIRUS TYPE II 
Poliomyelitis, Paralytic 045.13 ACUTE POLIOMYELITIS WITH OTH PARALYSIS, POLIOVIRUS TYPE III 
Psittacosis 073 ORNITHOSIS 
Psittacosis 073.0 ORNITHOSIS WITH PNEUMONIA 
Psittacosis 073.7 ORNITHOSIS WITH OTH SPEC COMPLICATIONS 
Psittacosis 073.8 ORNITHOSIS WITH UNSPEC COMPLICATION 
Psittacosis 073.9 ORNITHOSIS, UNSPEC 
Q Fever 083.0 Q FEVER 
Rabies, Human 071 RABIES 
RMSF 082.0 SPOTTED FEVERS 
Rubella 056 RUBELLA 
Rubella 056.0 RUBELLA WITH NEUROLOGICAL COMPLICATIONS 
Rubella 056.00 RUBELLA WITH UNSPEC NEUROLOGICAL COMPLICATION 
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Rubella 056.01 ENCEPHALOMYELITIS DUE TO RUBELLA 
Rubella 056.09 RUBELLA WITH OTH NEUROLOGICAL COMPLICATIONS 
Rubella 056.7 RUBELLA WITH OTH SPEC COMPLICATIONS 
Rubella 056.71 ARTHRITIS DUE TO RUBELLA 
Rubella 056.79 RUBELLA WITH OTH SPEC COMPLICATIONS 
Rubella 056.8 RUBELLA WITH UNSPEC COMPLICATIONS 
Rubella 056.9 RUBELLA NO COMPLICATION 
Rubella Congenital Syndrome 771.0 CONGENITAL RUBELLA 
Salmonellosis 003 OTH SALMONELLA INFEC 
Salmonellosis 003.0 SALMONELLA GASTROENTERITIS 
Salmonellosis 003.1 SALMONELLA SEPTICEMIA 
Salmonellosis 003.2 LOCALIZED SALMONELLA INFEC 
Salmonellosis 003.20 LOCALIZED SALMONELLA INFEC, UNSPEC 
Salmonellosis 003.21 SALMONELLA MENINGITIS 
Salmonellosis 003.22 SALMONELLA PNEUMONIA 
Salmonellosis 003.23 SALMONELLA ARTHRITIS 
Salmonellosis 003.24 SALMONELLA OSTEOMYELITIS 
Salmonellosis 003.29 OTH LOCALIZED SALMONELLA INFEC 
Salmonellosis 003.8 OTH SPEC SALMONELLA INFEC 
Salmonellosis 003.9 SALMONELLA INFEC, UNSPEC 
SARS (Coronavirus Infection) 480.3 PNEUMONIA DUE TO SARS-ASSOCIATED CORONAVIRUS 
SARS (Coronavirus Infection) 079.82 SARS-ASSOCIATED CORONAVIRUS 
Shigellosis 004 SHIGELLOSIS 
Shigellosis 004.0 SHIGELLA DYSENTERIAE 
Shigellosis 004.1 SHIGELLA FLEXNERI 
Shigellosis 004.2 SHIGELLA BOYDII 
Shigellosis 004.3 SHIGELLA SONNEI 
Shigellosis 004.8 OTH SPEC SHIGELLA INFEC 
Shigellosis 004.9 SHIGELLOSIS, UNSPEC 
Smallpox 050 SMALLPOX 
Smallpox 050.0 VARIOLA MAJOR 
Smallpox 050.1 ALASTRIM: VARIOLA MINOR 
Smallpox 050.2 MODIFIED SMALLPOX 
Smallpox 050.9 SMALLPOX, UNSPEC 
Streptococcal Infection, Invasive GAS 041.01 STREP INFEC IN OTH CONDITIONS AND OF UNSPEC SITE, STREP, GROUP A 
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Streptococcal Infection, Invasive GAS 038.0 STREPTOCOCCAL SEPTICEMIA 
Streptococcal Infection, Invasive GAS 320.2 STREPTOCOCCAL MENINGITIS  
Streptococcal Infection, Invasive GAS 482.31 GROUP A STREPTOCOCCAL PNEUMONIA 
Tetanus 037 TETANUS 
Toxic Shock Syndrome 040.82 TOXIC SHOCK SYNDROME 
Toxic Shock Syndrome, Streptococcal 040.82 TOXIC SHOCK SYNDROME 
Toxic Shock Syndrome, Streptococcal 041.01 GROUP A STREPTOCOCCUS 
Transmissible Spongiform Encephalo-
pathy (CJD/vCJD) 046.1 
JAKOB-CREUTZFELDT DISEASE 
Trichinosis 124 TRICHINOSIS 
Tuberculosis 010 PRIM TB INFEC 
Tuberculosis 010.0 PRIM TB COMPLEX 
Tuberculosis 010.00 PRIM TB COMPLEX, UNSPEC EXAM 
Tuberculosis 010.01 PRIM TB COMPLEX, BACTERIO/HISTO NOT DONE 
Tuberculosis 010.02 PRIM TB COMPLEX, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 010.03 PRIM TB COMPLEX, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 010.04 PRIM TB COMPLEX, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 010.05 PRIM TB COMPLEX, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 010.06 PRIM TB COMPLEX, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 010.1 PLEURISY IN PRIM PROGR TB 
Tuberculosis 010.10 PLEURISY IN PRIM PROGR TB, CONFIRMATION UNSPEC 
Tuberculosis 010.11 PLEURISY IN PRIM PROGR TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 010.12 PLEURISY IN PRIM PROGR TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 010.13 PLEURISY IN PRIM PROGR TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 010.14 PLEURISY IN PRIM PROGR TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 010.15 PLEURISY IN PRIM PROGR TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 010.16 PLEURISY IN PRIM PROGR TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 010.8 OTH PRIM PROGR TB 
Tuberculosis 010.80 OTH PRIM PROGR TB, CONFIRMATION UNSPEC 
Tuberculosis 010.81 OTH PRIM PROGR TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 010.82 OTH PRIM PROGR TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 010.83 OTH PRIM PROGR TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 010.84 OTH PRIM PROGR TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 010.85 OTH PRIM PROGR TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 010.86 OTH PRIM PROGR TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
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Tuberculosis 010.9 PRIM TB INFEC, UNSPEC 
Tuberculosis 010.90 PRIM TB INFEC, UNSPEC, CONFIRMATION UNSPEC 
Tuberculosis 010.91 PRIM TB INFEC, UNSPEC, BACTERIO/HISTO NOT DONE 
Tuberculosis 010.92 PRIM TB INFEC, UNSPEC, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 010.93 PRIM TB INFEC, UNSPEC, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 010.94 PRIM TB INFEC, UNSPEC, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 010.95 PRIM TB INFEC, UNSPEC, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 010.96 PRIM TB INFEC, UNSPEC, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011 PULM TB 
Tuberculosis 011.0 TB OF LUNG, INFILTRATIVE 
Tuberculosis 011.00 TB OF LUNG, INFILTRATIVE, CONFIRMATION UNSPEC 
Tuberculosis 011.01 TB OF LUNG, INFILTRATIVE, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.02 TB OF LUNG, INFILTRATIVE, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.03 TB OF LUNG, INFILTRATIVE, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.04 TB OF LUNG, INFILTRATIVE, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.05 TB OF LUNG, INFILTRATIVE, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.06 TB OF LUNG, INFILTRATIVE, BACILLI NOT BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.1 TB OF LUNG, NODULAR 
Tuberculosis 011.10 TB OF LUNG, NODULAR, UNSPEC EXAM 
Tuberculosis 011.11 TB OF LUNG, NODULAR, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.12 TB OF LUNG, NODULAR, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.13 TB OF LUNG, NODULAR, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.14 TB OF LUNG, NODULAR, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.15 TB OF LUNG, NODULAR, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.16 TB OF LUNG, NODULAR, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.2 TB OF LUNG WITH CAVITATION 
Tuberculosis 011.20 TB OF LUNG WITH CAVITATION, UNSPEC EXAM 
Tuberculosis 011.21 TB OF LUNG WITH CAVITATION, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.22 TB OF LUNG WITH CAVITATION, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.23 TB OF LUNG WITH CAVITATION, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.24 TB OF LUNG WITH CAVITATION, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.25 TB OF LUNG WITH CAVITATION, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.26 TB OF LUNG WITH CAVITATION, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.3 TB OF BRONCHUS 
Tuberculosis 011.30 TB OF BRONCHUS, UNSPEC EXAM 
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Tuberculosis 011.31 TB OF BRONCHUS, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.32 TB OF BRONCHUS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.33 TB OF BRONCHUS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.34 TB OF BRONCHUS, BACILLI NOT IN SPUTUM BY MICRO BUT FOUND IN BACT CX 
Tuberculosis 011.35 TB OF BRONCHUS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.36 TB OF BRONCHUS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.4 TB FIBROSIS OF LUNG 
Tuberculosis 011.40 TB FIBROSIS OF LUNG, UNSPEC EXAM 
Tuberculosis 011.41 TB FIBROSIS OF LUNG, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.42 TB FIBROSIS OF LUNG, BACTERIO/HISTOUNKNOWN 
Tuberculosis 011.43 TB FIBROSIS OF LUNG, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.44 TB FIBROSIS OF LUNG, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.45 TB FIBROSIS OF LUNG, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.46 TB FIBROSIS OF LUNG, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.5 TB BRONCHIECTASIS 
Tuberculosis 011.50 TB BRONCHIECTASIS, UNSPEC EXAM 
Tuberculosis 011.51 TB BRONCHIECTASIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.52 TB BRONCHIECTASIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.53 TB BRONCHIECTASIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.54 TB BRONCHIECTASIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.55 TB BRONCHIECTASIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.56 TB BRONCHIECTASIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.6 TB PNEUMONIA (ANY FORM) 
Tuberculosis 011.60 TB PNEUMONIA (ANY FORM), UNSPEC EXAM 
Tuberculosis 011.61 TB PNEUMONIA (ANY FORM), BACTERIO/HISTO NOT DONE 
Tuberculosis 011.62 TB PNEUMONIA (ANY FORM), BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.63 TB PNEUMONIA (ANY FORM), BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.64 TB PNEUMONIA (ANY FORM), BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.65 TB PNEUMONIA (ANY FORM), BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.66 TB PNEUMONIA (ANY FORM), BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.7 TB PNEUMOTHORAX 
Tuberculosis 011.70 TB PNEUMOTHORAX, UNSPEC EXAM 
Tuberculosis 011.71 TB PNEUMOTHORAX, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.72 TB PNEUMOTHORAX, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.73 TB PNEUMOTHORAX, BACILLI FOUND IN SPUTUM BY MICRO 
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Tuberculosis 011.74 TB PNEUMOTHORAX, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.75 TB PNEUMOTHORAX, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.76 TB PNEUMOTHORAX, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.8 OTH SPEC PULM TB 
Tuberculosis 011.80 OTH SPEC PULM TB, UNSPEC CONFIRMATION 
Tuberculosis 011.81 OTH SPEC PULM TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.82 OTH SPEC PULM TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.83 OTH SPEC PULM TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.84 OTH SPEC PULM TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.85 OTH SPEC PULM TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.86 OTH SPEC PULM TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 011.9 UNSPEC PULM TB 
Tuberculosis 011.90 UNSPEC PULM TB, CONFIRMATION UNSPEC 
Tuberculosis 011.91 UNSPEC PULM TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 011.92 UNSPEC PULM TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 011.93 UNSPEC PULM TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 011.94 UNSPEC PULM TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 011.95 UNSPEC PULM TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 011.96 UNSPEC PULM TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 012 OTH RESPIRATORY TB 
Tuberculosis 012.0 PLEURISY 
Tuberculosis 012.00 PLEURISY, CONFIRMATION UNSPEC 
Tuberculosis 012.01 PLEURISY, BACTERIO/HISTO NOT DONE 
Tuberculosis 012.02 PLEURISY, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 012.03 PLEURISY, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 012.04 PLEURISY, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 012.05 PLEURISY, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 012.06 PLEURISY, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 012.1 TB OF INTRATHORACIC LYMPH NODES 
Tuberculosis 012.10 TB OF INTRATHORACIC LYMPH NODES, CONFIRMATION UNSPEC 
Tuberculosis 012.11 TB OF INTRATHORACIC LYMPH NODES, BACTERIO/HISTO NOT DONE 
Tuberculosis 012.12 TB OF INTRATHORACIC LYMPH NODES, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 012.13 TB OF INTRATHORACIC LYMPH NODES, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 012.14 
TB OF INTRATHORACIC LYMPH NODES, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT 
CX 
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Tuberculosis 012.15 TB OF INTRATHORACIC LYMPH NODES, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 012.16 
TB OF INTRATHORACIC LYMPH NODES, BACILLI NOT BY BACTERIO/HISTO BUT OTH 
METHOD 
Tuberculosis 012.2 ISOLATED TRACH OR BRONCH TB 
Tuberculosis 012.20 ISOLATED TRACH OR BRONCH TB, UNSPEC EXAM 
Tuberculosis 012.21 ISOLATED TRACH OR BRONCH TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 012.22 ISOLATED TRACH OR BRONCH TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 012.23 ISOLATED TRACH OR BRONCH TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 012.24 ISOLATED TRACH OR BRONCH TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 012.25 ISOLATED TRACH OR BRONCH TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 012.26 ISOLATED TRACH OR BRONCH TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 012.3 TB LARYNGITIS 
Tuberculosis 012.30 TB LARYNGITIS, UNSPEC EXAM 
Tuberculosis 012.31 TB LARYNGITIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 012.32 TB LARYNGITIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 012.33 TB LARYNGITIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 012.34 TB LARYNGITIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 012.35 TB LARYNGITIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 012.36 TB LARYNGITIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 012.8 OTH SPEC RESPIRATORY TB 
Tuberculosis 012.80 OTH SPEC RESPIRATORY TB, UNSPEC EXAM 
Tuberculosis 012.81 OTH SPEC RESPIRATORY TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 012.82 OTH SPEC RESPIRATORY TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 012.83 OTH SPEC RESPIRATORY TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 012.84 OTH SPEC RESPIRATORY TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 012.85 OTH SPEC RESPIRATORY TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 012.86 OTH SPEC RESPIRATORY TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013 TB OF MENINGES AND CNS 
Tuberculosis 013.0 TB MENINGITIS 
Tuberculosis 013.00 TB MENINGITIS, UNSPEC EXAM 
Tuberculosis 013.01 TB MENINGITIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.02 TB MENINGITIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.03 TB MENINGITIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.04 TB MENINGITIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.05 TB MENINGITIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
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Tuberculosis 013.06 TB MENINGITIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.1 TUBERCULOMA OF MENINGES 
Tuberculosis 013.10 TUBERCULOMA OF MENINGES, UNSPEC EXAM 
Tuberculosis 013.11 TUBERCULOMA OF MENINGES, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.12 TUBERCULOMA OF MENINGES, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.13 TUBERCULOMA OF MENINGES, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.14 TUBERCULOMA OF MENINGES, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.15 TUBERCULOMA OF MENINGES, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.16 TUBERCULOMA OF MENINGES, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.2 TUBERCULOMA OF BRAIN 
Tuberculosis 013.20 TUBERCULOMA OF BRAIN, UNSPEC EXAM 
Tuberculosis 013.21 TUBERCULOMA OF BRAIN, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.22 TUBERCULOMA OF BRAIN, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.23 TUBERCULOMA OF BRAIN, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.24 TUBERCULOMA OF BRAIN, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.25 TUBERCULOMA OF BRAIN, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.26 TUBERCULOMA OF BRAIN, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.3 TB ABSCESS OF BRAIN 
Tuberculosis 013.30 TB ABSCESS OF BRAIN, UNSPEC EXAM 
Tuberculosis 013.31 TB ABSCESS OF BRAIN, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.32 TB ABSCESS OF BRAIN, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.33 TB ABSCESS OF BRAIN, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.34 TB ABSCESS OF BRAIN, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.35 TB ABSCESS OF BRAIN, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.36 TB ABSCESS OF BRAIN, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.4 TUBERCULOMA OF SPINAL CORD 
Tuberculosis 013.40 TUBERCULOMA OF SPINAL CORD, UNSPEC EXAM 
Tuberculosis 013.41 TUBERCULOMA OF SPINAL CORD, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.42 TUBERCULOMA OF SPINAL CORD, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.43 TUBERCULOMA OF SPINAL CORD, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.44 TUBERCULOMA OF SPINAL CORD, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.45 TUBERCULOMA OF SPINAL CORD, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.46 TUBERCULOMA OF SPINAL CORD, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.5 TB ABSCESS OF SPINAL CORD 
Tuberculosis 013.50 TB ABSCESS OF SPINAL CORD, UNSPEC EXAM 
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Tuberculosis 013.51 TB ABSCESS OF SPINAL CORD, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.52 TB ABSCESS OF SPINAL CORD, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.53 TB ABSCESS OF SPINAL CORD, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.54 TB ABSCESS OF SPINAL CORD, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.55 TB ABSCESS OF SPINAL CORD, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.56 TB ABSCESS OF SPINAL CORD, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.6 TB ENCEPHALITIS OR MYELITIS 
Tuberculosis 013.60 TB ENCEPHALITIS OR MYELITIS, UNSPEC EXAM 
Tuberculosis 013.61 TB ENCEPHALITIS OR MYELITIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.62 TB ENCEPHALITIS OR MYELITIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.63 TB ENCEPHALITIS OR MYELITIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.64 TB ENCEPHALITIS OR MYELITIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.65 TB ENCEPHALITIS OR MYELITIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.66 TB ENCEPHALITIS OR MYELITIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.8 OTH SPEC TB OF CNS 
Tuberculosis 013.80 OTH SPEC TB OF CNS, UNSPEC EXAM 
Tuberculosis 013.81 OTH SPEC TB OF CNS, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.82 OTH SPEC TB OF CNS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.83 OTH SPEC TB OF CNS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.84 OTH SPEC TB OF CNS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.85 OTH SPEC TB OF CNS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.86 OTH SPEC TB OF CNS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 013.9 UNSPEC TB OF CNS 
Tuberculosis 013.90 UNSPEC TB OF CNS, UNSPEC EXAM 
Tuberculosis 013.91 UNSPEC TB OF CNS, BACTERIO/HISTO NOT DONE 
Tuberculosis 013.92 UNSPEC TB OF CNS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 013.93 UNSPEC TB OF CNS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 013.94 UNSPEC TB OF CNS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 013.95 UNSPEC TB OF CNS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 013.96 UNSPEC TB OF CNS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 014 TB OF INTESTINES, PERITONEUM, AND MESENTERIC GLANDS 
Tuberculosis 014.0 TB PERITONITIS 
Tuberculosis 014.00 TB PERITONITIS, UNSPEC EXAM 
Tuberculosis 014.01 TB PERITONITIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 014.02 TB PERITONITIS, BACTERIO/HISTO RESULTS UNKNOWN 
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Tuberculosis 014.03 TB PERITONITIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 014.04 TB PERITONITIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 014.05 TB PERITONITIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 014.06 TB PERITONITIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 014.8 OTH TB OF INTESTINES, PERITONEUM AND MESENTERIC GLANDS 
Tuberculosis 014.80 OTH TB INTEST AND MESEN GLANDS, UNSPEC EXAM 
Tuberculosis 014.81 OTH TB INTEST AND MESEN GLANDS, BACTERIO/HISTO NOT DONE 
Tuberculosis 014.82 OTH TB INTEST AND MESEN GLANDS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 014.83 OTH TB INTEST AND MESEN GLANDS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 014.84 OTH TB INTEST AND MESEN GLANDS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 014.85 OTH TB INTEST AND MESEN GLANDS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 014.86 OTH TB INTEST AND MESEN GLANDS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015 TB OF BONES AND JOINTS 
Tuberculosis 015.0 TB OF VERTEBRAL COLUMN 
Tuberculosis 015.00 TB OF VERTEBRAL COLUMN, UNSPEC EXAM 
Tuberculosis 015.01 TB OF VERTEBRAL COLUMN, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.02 TB OF VERTEBRAL COLUMN, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.03 TB OF VERTEBRAL COLUMN, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.04 TB OF VERTEBRAL COLUMN, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.05 TB OF VERTEBRAL COLUMN, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.06 TB OF VERTEBRAL COLUMN, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.1 TB OF HIP 
Tuberculosis 015.10 TB OF HIP, UNSPEC EXAM 
Tuberculosis 015.11 TB OF HIP, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.12 TB OF HIP, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.13 TB OF HIP, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.14 TB OF HIP, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.15 TB OF HIP, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.16 TB OF HIP, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.2 TB OF KNEE 
Tuberculosis 015.20 TB OF KNEE, UNSPEC EXAM 
Tuberculosis 015.21 TB OF KNEE, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.22 TB OF KNEE, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.23 TB OF KNEE, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.24 TB OF KNEE, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
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Tuberculosis 015.25 TB OF KNEE, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.26 TB OF KNEE, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.5 TB OF LIMB BONES 
Tuberculosis 015.50 TB OF LIMB BONES, UNSPEC EXAM 
Tuberculosis 015.51 TB OF LIMB BONES, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.52 TB OF LIMB BONES, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.53 TB OF LIMB BONES, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.54 TB OF LIMB BONES, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.55 TB OF LIMB BONES, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.56 TB OF LIMB BONES, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.6 TB OF MASTOID 
Tuberculosis 015.60 TB OF MASTOID, UNSPEC EXAM 
Tuberculosis 015.61 TB OF MASTOID, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.62 TB OF MASTOID, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.63 TB OF MASTOID, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.64 TB OF MASTOID, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.65 TB OF MASTOID, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.66 TB OF MASTOID, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.7 TB OF OTH SPEC BONE 
Tuberculosis 015.70 TB OF OTH SPEC BONE, UNSPEC EXAM 
Tuberculosis 015.71 TB OF OTH SPEC BONE, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.72 TB OF OTH SPEC BONE, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.73 TB OF OTH SPEC BONE, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.74 TB OF OTH SPEC BONE, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.75 TB OF OTH SPEC BONE, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.76 TB OF OTH SPEC BONE, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.8 TB OF OTH SPEC JOINT 
Tuberculosis 015.80 TB OF OTH SPEC JOINT, UNSPEC EXAM 
Tuberculosis 015.81 TB OF OTH SPEC JOINT, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.82 TB OF OTH SPEC JOINT, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.83 TB OF OTH SPEC JOINT, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.84 TB OF OTH SPEC JOINT, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.85 TB OF OTH SPEC JOINT, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.86 TB OF OTH SPEC JOINT, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 015.9 TB OF UNSPEC BONES AND JOINTS 
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Tuberculosis 015.90 TB OF UNSPEC BONES AND JOINTS, UNSPEC EXAM 
Tuberculosis 015.91 TB OF UNSPEC BONES AND JOINTS, BACTERIO/HISTO NOT DONE 
Tuberculosis 015.92 TB OF UNSPEC BONES AND JOINTS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 015.93 TB OF UNSPEC BONES AND JOINTS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 015.94 TB OF UNSPEC BONES AND JOINTS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 015.95 TB OF UNSPEC BONES AND JOINTS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 015.96 TB OF UNSPEC BONES AND JOINTS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016 TB OF GENITOURINARY SYSTEM 
Tuberculosis 016.0 TB OF KIDNEY 
Tuberculosis 016.00 TB OF KIDNEY, UNSPEC EXAM 
Tuberculosis 016.01 TB OF KIDNEY, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.02 TB OF KIDNEY, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.03 TB OF KIDNEY, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.04 TB OF KIDNEY, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.05 TB OF KIDNEY, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.06 TB OF KIDNEY, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.1 TB OF BLADDER 
Tuberculosis 016.10 TB OF BLADDER, UNSPEC EXAM 
Tuberculosis 016.11 TB OF BLADDER, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.12 TB OF BLADDER, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.13 TB OF BLADDER, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.14 TB OF BLADDER, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.15 TB OF BLADDER, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.16 TB OF BLADDER, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.2 TB OF URETER 
Tuberculosis 016.20 TB OF URETER, UNSPEC EXAM 
Tuberculosis 016.21 TB OF URETER, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.22 TB OF URETER, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.23 TB OF URETER, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.24 TB OF URETER, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.25 TB OF URETER, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.26 TB OF URETER, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.3 TB OF OTH URINARY ORGANS 
Tuberculosis 016.30 TB OF OTH URINARY ORGANS, UNSPEC EXAM 
Tuberculosis 016.31 TB OF OTH URINARY ORGANS, BACTERIO/HISTO NOT DONE 
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Tuberculosis 016.32 TB OF OTH URINARY ORGANS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.33 TB OF OTH URINARY ORGANS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.34 TB OF OTH URINARY ORGANS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.35 TB OF OTH URINARY ORGANS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.36 TB OF OTH URINARY ORGANS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.4 TB OF EPIDIDYMIS 
Tuberculosis 016.40 TB OF EPIDIDYMIS, UNSPEC EXAM 
Tuberculosis 016.41 TB OF EPIDIDYMIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.42 TB OF EPIDIDYMIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.43 TB OF EPIDIDYMIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.44 TB OF EPIDIDYMIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.45 TB OF EPIDIDYMIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.46 TB OF EPIDIDYMIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.5 TB OF OTH MALE GENITAL ORGANS 
Tuberculosis 016.50 TB OF OTH MALE GENITAL ORGANS, UNSPEC EXAM 
Tuberculosis 016.51 TB OF OTH MALE GENITAL ORGANS, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.52 TB OF OTH MALE GENITAL ORGANS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.53 TB OF OTH MALE GENITAL ORGANS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.54 TB OF OTH MALE GENITAL ORGANS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.55 TB OF OTH MALE GENITAL ORGANS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.56 TB OF OTH MALE GENITAL ORGANS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.6 TB OOPHORITIS AND SALPINGITIS 
Tuberculosis 016.60 TB OOPHORITIS AND SALPINGITIS, UNSPEC EXAM 
Tuberculosis 016.61 TB OOPHORITIS AND SALPINGITIS, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.62 TB OOPHORITIS AND SALPINGITIS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.63 TB OOPHORITIS AND SALPINGITIS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.64 TB OOPHORITIS AND SALPINGITIS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.65 TB OOPHORITIS AND SALPINGITIS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.66 TB OOPHORITIS AND SALPINGITIS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 016.7 TB OF OTH FEMALE GENITAL ORGANS 
Tuberculosis 016.70 TB OF OTH FEMALE GENITAL ORGANS, UNSPEC EXAM 
Tuberculosis 016.71 TB OF OTH FEMALE GENITAL ORGANS, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.72 TB OF OTH FEMALE GENITAL ORGANS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.73 TB OF OTH FEMALE GENITAL ORGANS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.74 TB OF OTH FEMALE GENITAL ORGANS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT 
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CX 
Tuberculosis 016.75 TB OF OTH FEMALE GENITAL ORGANS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.76 
TB OF OTH FEMALE GENITAL ORGANS, BACILLI NOT BY BACTERIO/HISTO BUT OTH 
METHOD 
Tuberculosis 016.9 GENITOURINARY TB, UNSPEC 
Tuberculosis 016.90 UNSPEC GENITOURINARY TB, UNSPEC EXAM 
Tuberculosis 016.91 UNSPEC GENITOURINARY TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 016.92 UNSPEC GENITOURINARY TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 016.93 UNSPEC GENITOURINARY TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 016.94 UNSPEC GENITOURINARY TB, TB BA CILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 016.95 UNSPEC GENITOURINARY TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 016.96 UNSPEC GENITOURINARY TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017 TB OF OTH ORGANS 
Tuberculosis 017.0 TB OF SKIN AND SUBCU TISSUE 
Tuberculosis 017.00 TB OF SKIN AND SUBCU TISSUE, UNSPEC EXAM 
Tuberculosis 017.01 TB OF SKIN AND SUBCU TISSUE, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.02 TB OF SKIN AND SUBCU TISSUE, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.03 TB OF SKIN AND SUBCU TISSUE, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.04 TB OF SKIN AND SUBCU TISSUE, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.05 TB OF SKIN AND SUBCU TISSUE, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.06 TB OF SKIN AND SUBCU TISSUE, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.1 ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB 
Tuberculosis 017.10 ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB, UNSPEC EXAM 
Tuberculosis 017.11 ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.12 ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.13 ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.14 
ERY NODOSUM W/HYPERSENS RXN IN TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY 
BACT CX 
Tuberculosis 017.15 
ERYTHEMA NODOSUM W/HYPERSENS RXN IN TB, BACILLI NOT BY BACTERIO EXAM BUT 
HISTO 
Tuberculosis 017.16 
ERY NODOSUM W/HYPERSENS RXN IN TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH 
METHOD 
Tuberculosis 017.2 TB OF PERIPH LYMPH NODES 
Tuberculosis 017.20 TB OF PERIPH LYMPH NODES, UNSPEC EXAM 
Tuberculosis 017.21 TB OF PERIPH LYMPH NODES, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.22 TB OF PERIPH LYMPH NODES, BACTERIO/HISTO RESULTS UNKNOWN 
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Tuberculosis 017.23 TB OF PERIPH LYMPH NODES, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.24 TB OF PERIPH LYMPH NODES, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.25 TB OF PERIPH LYMPH NODES, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.26 TB OF PERIPH LYMPH NODES, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.3 TB OF EYE 
Tuberculosis 017.30 TB OF EYE, UNSPEC EXAM 
Tuberculosis 017.31 TB OF EYE, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.32 TB OF EYE, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.33 TB OF EYE, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.34 TB OF EYE, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.35 TB OF EYE, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.36 TB OF EYE, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.4 TB OF EAR 
Tuberculosis 017.40 TB OF EAR, UNSPEC EXAM 
Tuberculosis 017.41 TB OF EAR, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.42 TB OF EAR, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.43 TB OF EAR, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.44 TB OF EAR, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.45 TB OF EAR, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.46 TB OF EAR, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.5 TB OF THYROID GLAND 
Tuberculosis 017.50 TB OF THYROID GLAND, UNSPEC ORIGIN 
Tuberculosis 017.51 TB OF THYROID GLAND, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.52 TB OF THYROID GLAND, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.53 TB OF THYROID GLAND, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.54 TB OF THYROID GLAND, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.55 TB OF THYROID GLAND, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.56 TB OF THYROID GLAND, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.6 TB OF ADRENAL GLANDS 
Tuberculosis 017.60 TB OF ADRENAL GLANDS, UNSPEC EXAM 
Tuberculosis 017.61 TB OF ADRENAL GLANDS, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.62 TB OF ADRENAL GLANDS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.63 TB OF ADRENAL GLANDS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.64 TB OF ADRENAL GLANDS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.65 TB OF ADRENAL GLANDS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
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Tuberculosis 017.66 TB OF ADRENAL GLANDS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.7 TB OF SPLEEN 
Tuberculosis 017.70 TB OF SPLEEN, UNSPEC EXAM 
Tuberculosis 017.71 TB OF SPLEEN, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.72 TB OF SPLEEN, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.73 TB OF SPLEEN, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.74 TB OF SPLEEN, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.75 TB OF SPLEEN, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.76 TB OF SPLEEN, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.8 TB OF ESOPHAGUS 
Tuberculosis 017.80 TB OF ESOPHAGUS, UNSPEC EXAM 
Tuberculosis 017.81 TB OF ESOPHAGUS, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.82 TB OF ESOPHAGUS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.83 TB OF ESOPHAGUS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.84 TB OF ESOPHAGUS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.85 TB OF ESOPHAGUS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.86 TB OF ESOPHAGUS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 017.9 TB OF OTH SPEC ORGANS 
Tuberculosis 017.90 TB OF OTH SPEC ORGANS, UNSPEC EXAM 
Tuberculosis 017.91 TB OF OTH SPEC ORGANS, BACTERIO/HISTO NOT DONE 
Tuberculosis 017.92 TB OF OTH SPEC ORGANS, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 017.93 TB OF OTH SPEC ORGANS, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 017.94 TB OF OTH SPEC ORGANS, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 017.95 TB OF OTH SPEC ORGANS, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 017.96 TB OF OTH SPEC ORGANS, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 018 MILIARY TB 
Tuberculosis 018.0 ACUTE MILIARY TB 
Tuberculosis 018.00 ACUTE MILIARY TB, UNSPEC EXAM 
Tuberculosis 018.01 ACUTE MILIARY TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 018.02 ACUTE MILIARY TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 018.03 ACUTE MILIARY TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 018.04 ACUTE MILIARY TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 018.05 ACUTE MILIARY TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 018.06 ACUTE MILIARY TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 018.8 OTH SPEC MILIARY TB 
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Tuberculosis 018.80 OTH SPEC MILIARY TB, UNSPEC EXAM 
Tuberculosis 018.81 OTH SPEC MILIARY TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 018.82 OTH SPEC MILIARY TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 018.83 OTH SPEC MILIARY TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 018.84 OTH SPEC MILIARY TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 018.85 OTH SPEC MILIARY TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 018.86 OTH SPEC MILIARY TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tuberculosis 018.9 UNSPEC MILIARY TB 
Tuberculosis 018.90 UNSPEC MILIARY TB, UNSPEC EXAM 
Tuberculosis 018.91 UNSPEC MILIARY TB, BACTERIO/HISTO NOT DONE 
Tuberculosis 018.92 UNSPEC MILIARY TB, BACTERIO/HISTO RESULTS UNKNOWN 
Tuberculosis 018.93 UNSPEC MILIARY TB, BACILLI FOUND IN SPUTUM BY MICRO 
Tuberculosis 018.94 UNSPEC MILIARY TB, BACILLI NOT IN SPUTUM BY MICRO BUT BY BACT CX 
Tuberculosis 018.95 UNSPEC MILIARY TB, BACILLI NOT BY BACTERIO EXAM BUT HISTO 
Tuberculosis 018.96 UNSPEC MILIARY TB, BACILLI NOT BY BACTERIO/HISTO BUT OTH METHOD 
Tularemia 021 TULAREMIA 
Tularemia 021.0 ULCEROGLANDULAR TULAREMIA 
Tularemia 021.1 ENTERIC TULAREMIA 
Tularemia 021.2 PULM TULAREMIA 
Tularemia 021.3 OCULOGLANDULAR TULAREMIA 
Tularemia 021.8 OTH SPEC TULAREMIA 
Tularemia 021.9 UNSPEC TULAREMIA 
Typhoid, Acute 002.0 TYPHOID FEVER 
Typhus, Epidemic 080 LOUSE-BORNE (EPIDEMIC) TYPHUS 
Vaccinia 999.0 GENERALIZED VACCINIA 
Vaccinia 051.0 COWPOX 
Vibrio infection, other 005.4 FOOD POISIONING DUE TO VIBRIO PARAHAEMOLYTICUS 
Vibrio vulnificus 005.81 FOOD POISONING DUE TO VIBRIO VULNIFICUS 
Whooping Cough 033.0 WHOOPING COUGH DUE TO BORDETELLA PERTUSSIS (B. PERTUSSIS) 
Whooping Cough 484.3 PNEUMONIA IN WHOOPING COUGH 
Yellow Fever 060 YELLOW FEVER 
Yellow Fever 060.0 SYLVATIC YELLOW FEVER 
Yellow Fever 060.1 URBAN YELLOW FEVER 
Yellow Fever 060.9 YELLOW FEVER, UNSPEC 
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Appendix 2:  Sample Data Request 
Data Request Methodology 
 
Retrospective Cohort Study: 
Definition of the cohort:  All patients (e.g., outpatients, inpatients, ED patients) at your healthcare fa-
cility who were assigned one of the listed ICD9 diagnostic codes for a communicable disease and 
who were either discharged or had an outpatient visit date during the following time periods:  January 
1, 1995 to December 31, 1997 and January 1, 2000 to December 31, 2006. 
 
Data collection:  For each patient in the cohort, please collect the following data elements (as they are 
available at your institution) from the department that maintains discharge data (e.g., billing, medical 
coding, medical records).  Please request your data abstracting department to provide you with a line 
list of these patients with the data in Microsoft Excel format). 
 
For each patient: 
a. Healthcare facility  
b. Name (first, middle, last)* 
c. Hospital identification number* 
d. Social security number 
e. Address 
f. Zip code 
g. County of residence 
h. Date of birth* 
i. Gender 
j. Race 
k. Discharge diagnosis code(s) (ICD-9 codes)* 
l. Discharge diagnosis description* 
m. Procedure codes 
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n. Outpatient physician seen, discharge physician seen 
o. Insurance type 
p. Nursing unit 
q. Hospital service 
r. Discharge status 
s. Site of care (i.e., inpatient, outpatient, emergency) 
t. Admission date (for inpatient)* 
u. Discharge date (for inpatient)* 
v. Date of service (for outpatient)* 
 
* Starred data elements are required in order to complete the basic objectives of this study, other data 
elements are also requested for analysis, but if not available in the discharge data database can be 
omitted. 
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Appendix 3:  Example Application of Bayes Theorem for Adjustment of ICD-9-CM-based Complete-
ness Studies 
 
 
 
 
 
 
 
 
 
 
R =Reported to the State surveillance system 
C =Meets the CDC case definition 
I =Assigned an ICD-9-CM code for a communicable disease 
 
P(R|C) = P(C|R) P(R) 
        P(C) 
 
  = P(C|R) P(R|I) P(I) 
             P(C)     P(I|R)  
 
  = P(C|R) P(I|C) P(R|I) P(I) 
        P(C|I) P(I)  P(I|R)  
 
  = P(C|R) P(I|C) P(R|I)  
         P(I|R) P(C|I) 
 
Reported 
Yes No 
ICD-9 
Code for Communi-
cable Disease 
CDC 
Disease A1 B1 
CDC 
No Disease C1=0 D1 
No ICD-9 
Code for Communi-
cable Disease 
CDC 
Disease 
A2 
(Not Meas-
ured) 
B2 
(Not Meas-
ured) 
CDC 
No Disease C2=0 
D2 
(Not Meas-
ured) 
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Estimates: 
P(C|R)=1, because if a disease is reported it should meet CDC case definition 
P(I|C)=  sensitivity values estimated = (A1+B1)/(A1+B1+A2+B2) 
P(R|I)=  completeness proportions estimated 
P(I|R) = (A1)/(A1+A2)  
P(C|I)= positive predictive values estimated 
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